Podcasts about GIP

What if the reason you’re not healing isn’t that you need another diagnosis? 0:08 It’s that your cells aren’t receiving the right signals. Because the body doesn’t run on diagnosis, it runs on 0:16 communication. And peptides are one of the most powerful, most misunderstood 0:21 tools we have for cellular signaling, immune balance, tissue repair, gut 0:27 lining support, metabolic control, brain signaling, sleep cycles, and even sexual 0:35 wellness. Today, I’m going to do what most people won’t. Define peptides in 0:41 plain English for you. break them into categories by what they’re best at and 0:47 tell you which ones are FDA approved on the list and which ones are commonly 0:53 used off label or investigational with the evidence that actually says these 1:00 work. This is going to be a powerful episode and if you’ve ever felt like you’re hearing hype without clarity, 1:07 this one’s for you. So, as usual, grab your cup of coffee or tea and settle in 1:13 as we talk about peptides that can fit into your healing journey. We’re going 1:19 to have a short word from our sponsor. You know, we got to do that. That’s how we stay on the air here. So, we will be 1:26 right back after this. Did you know sweating can literally heal your cells? 1:32I nfrared saunas don’t just relax you. They detox your body, balance hormones, 1:37 and boost mitochondrial energy. I’m obsessed with my health tech sauna. And 1:42 right now, you can save $500 with my code at healthtechalth.com/drmuthqen25. 1:54 All right, here we go, guys. I am excited to dive into peptides with you. 2:00 So understanding peptides is foundational, right? And I’ve been 2:06 studying peptides now for about nine years. Um, and I find that they are 2:13 incredible. Um, so I want to break down for you what peptides actually are, what 2:19 they do, and some of the top peptides that are available today, and how they 2:25 can be utilized. Because I think it’s really important. And I think it’s it’s there’s a lot of confusion out there about what these things actually are and 2:32 are they safe? Are they not? When do we use them? What’s the science behind them? So, we’re going to dive in and 2:38 we’re going to talk about all things peptides. So, let’s get ready here. Here we go. So, peptides are short chains of 2:45 amino acids and they typically range anywhere from 2 to 50 amino acids and 2:51 they’re linked by peptide bonds. So think of them as the superglue that holds the amino acids together. They sit 2:58 between the amino acids and they are full proteins in terms of their size and 3:04 their complex structure. And what makes peptides particularly interesting in 3:10 medicine is their role as signaling molecules. They’re essentially the 3:15 body’s text messages carrying specific instructions to cells and tissues. And 3:21 unlike our proteins which often serve as structural roles or act as enzymes, 3:28 peptides typically function as hormones, neurotransmitters and growth factors and 3:33 they bind to specific receptors on the cell’s surfaces or within the cells and 3:39 they trigger this effect. It’s like a cascade effect of a biochemical reaction 3:45 that ultimately changes the cellular behavior. So basically, it’s changing 3:50 the way the body’s cell structure acts. And this is why peptides can be so 3:56 incredibly powerful and therapeutic when you introduce the right peptide signal. 4:02 Now, you could theoretically redirect cellular processes toward healing, 4:07 towards metabolism, immune balance, tissue repair. Any of those things can 4:14 be manipulated to do a certain thing once we add the peptide. The challenge 4:19 in peptide medicine though lies in distinguishing between those peptides that have been rigorously studied, 4:26 proven safe and effective and approved by regulatory bodies like the FDA versus 4:31 those that exist in what we call the gray zone of a promising clinical data. 4:36 But they really lack human validation so far. And this distinction is critical because the presence of a plausible 4:43 mechanism does not guarantee safety or efficacy in living humans. So, this is 4:50 really important and we’re going to dive in and look at some of the research on all of these different peptides that are 4:56 available and I’m excited to say there’s some amazing peptides being studied right now that unfortunately are not 5:01 available. But I can’t wait to see them hit the market for us because it is going to be a gamecher as far as health 5:09 and longevity. So there is a quality control issue and there is a hidden 5:14 variable in peptide medicine with this and it’s one of the most underappreciated aspects of peptide 5:21 therapy particularly for non-FDA approved peptides. It’s quality control. 5:26 When we discuss pharmaceutical medicines, we take for granted that the pill contains what the label says. Not 5:32 always true depending on where it comes from. You guys, if you’ve heard my episodes before talk about how many of our medications are made in China and 5:41 have been contaminated with other things, you will realize that that is not always true. So, just because it has 5:48 the FDA stamp of approval on the medication, it still does not necessarily mean it’s safe and we still 5:54 need to do our homework on it. So, sorry for digressing on you guys, but you know, when we get a medication, we we 6:00 think that what the amount says is what is there, doesn’t have contaminants, it’s manufactured with good 6:06 manufacturing practices. You’ll see that listed as GMP on the bottle, and it’s been stored properly, it’s been 6:12 maintained stable, and with research peptides and compounded formulations, 6:17 none of this can be assumed. So, I will share a story with you. There was a gentleman that was purchasing these 6:24 peptides online from a research facility and um did not know that they were 6:30 coming from China and he was ordering a particular growth hormone peptide and 6:35 after a little while he had he had done fine for the few first few bottles. After a little while he started having 6:42 some complications. He started getting really irritable and angry and ragy and 6:47 he didn’t quite know what was going on. And so he decided to go get some testing done. He had some blood testing done and 6:53 his testosterone level was over 5,000. So for those of you who know what testosterone level should be for a guy, 7:00 they really shouldn’t be any higher than about 1,00200 would be absolute max that we’d want to see. Now he was taking 7:06 testosterone but not to that degree. And prior to adding this peptide, his 7:12 testosterone was very stable. What they ended up finding out was the peptide that he was getting, whoever was 7:18 manufacturing it added testosterone to the peptide. They felt like if if it had growth hormone, that was great, but if 7:25 it had growth hormone and tes testosterone, all the better. And he didn’t know that. And this is the 7:31 problem that we can have with peptides if you don’t source them properly. if you’re not working with somebody that 7:37 knows how to source them and can prove that they are what they say they are. Um, I’m sure there’s a whole bunch of 7:42 studies out there too of people getting these peptides and paying hundreds of thousands of dollars for them over their 7:48 lifetime and finding out they were nothing more than just sterile water. So, you really do need to be careful 7:53 with your quality control. Now, this kind of leads us right into the next topic that we’re going to talk about and that’s the manufacturing question, 8:00 right? The FDA approved peptides are manufactured in facilities subject to 8:05 the FDA inspection rules following our GMP regulations and these facilities 8:11 must validate their manufacturing process, demonstrate consistency batch to batch, test for purity and potency. 8:18 They need to test for bacterial endotoxins and sterility and they need to maintain detailed records. So, when a 8:25 pharmaceutical company submits a drug application, the FDA inspects the manufacturing facility as part of the 8:32 approval process. If you’re getting peptides from a different country, none of that is happening. And there are some 8:38 ways for us to determine if that is what you’re getting. Typically, the rule of thumb is if your peptides are coming 8:44 with a different colored top, every one of them has a different colored top. Those are typically being sourced out of 8:49 China. I wouldn’t say that’s 100% but that’s kind of the rule of thumb that people follow. So compoundingies these 8:56 are thearmacies that make our bio identical hormones. They can make medications in any dose or strength or 9:02 route. There are thousands of them in every not that not in every state but 9:08 there are thousands of them around the country right now. So these compoundingies are registered as 503A 9:15 facilities. They do traditional compounding for individual prescriptions, right? Like they can make 9:20 thyroid, they can make LDN, they can make estrogen. You can also have a 503b 9:27 facility, which is an outsourcing facility. And these companies produce larger batches of products. They’re they 9:34 have some oversight, but they’re less stringent than for FDA approved 9:40 manufacturers. And state boards of pharmacy regulate a 503A pharmacy. And 9:45 the FDA can inspect the 503b facility, but doesn’t preapprove any of their 9:52 compounding products. So, they can inspect it, but they don’t approve them. So, research chemicals and these 9:58 suppliers operate essentially with no oversight. They explicitly market products for research use only, not for 10:06 human consumption to avoid FDA regulation. If they put that on their 10:12 product, they don’t have to comply to what the FDA is saying. And there is no required manufacturing strategies or 10:19 standards, no required testing, no required sterility assurance, and no enforcement mechanisms if products are 10:26 mislabeled or contaminated. So basically, they don’t have the liability, but that doesn’t mean that 10:31 all of them are badies or bad suppliers. It just means they don’t have to comply 10:37 to the FDA rules. Now, there are many of these companies that I’ve seen and I’ve talked to that do do a lot of this. They 10:44 do test their product for sterility. They do test their product to make sure it is what it says it is. They don’t 10:51 have to, but they do. So, if you’re going to decide to use a company that 10:56 has research only, not for human consumption, at least ask for their 11:02 proof of testing so that you know that the product you’re getting is what it says it is and that it’s clean. Because 11:08 this is where we run into the problem is in purity. So in purity peptide 11:13 synthesis can produce not just the targeted peptide but also related 11:19 peptides with deletions, substitutions, truncations or truncations of amino 11:25 acids. Sorry. And this high performance liquid we call it uh chromatography can 11:30 separate these related impurities and quality and quantify the actual target 11:35 of the peptide content. So a certificate of analysis is what you want to ask these companies for. This shows the HPLC 11:44 the testing mechanism with greater than 95% or ideally 98% purity which 11:51 indicates a higher quality product. So this certificate of analysis can be fabricated may not represent the 11:57 specific batch being sold. It happens. We need to know not everybody is honest. Not everybody, you know, does what they 12:03 say and it does what’s right. But at least you at least they’re giving you something and you have some security. 12:10 and then choose a company that was referred to by someone else that has done some homework as well. In in 12:16 commercial research, there’s independent testing and they research peptides and this has been really shocking 12:23 variability that they’ve seen. Some products contain 50% or less of the 12:29 claimed peptide and some contained primarily degradation of the product or manufacturing impurities and some 12:36 contained bacterial endotoxins at levels that could cause fever and systemic 12:42 inflammation if it was truly injected. And I would also worry with some of those problems, you know, depending on 12:48 what impurity or bacterial endotoxin was there. If you’re using a product to boost your immune system and your immune 12:54 system is already compromised, these bacterial endotoxins can actually make you sicker instead of what you want it 13:02 to do, which is making you better. So, sterility is always an issue with anything that is manufactured, 13:08 especially things that we’re doing as an injection. Peptides are intended for injection. They must be sterile. They 13:16 must be kept safe. And pharmaceutical manufacturers conduct this sterility testing on every batch. 13:22 Compoundingarmacies should conduct sterility testing particularly for high-risisk compounded 13:28 sterile preparations and research chemical suppliers may or may not conduct any testing. So injecting 13:35 non-sterile material can cause local infections, abscesses at the injection 13:41 site and or if the bacteria enters the bloodstream could potentially be 13:46 life-threatening and you could have sepsis. Now, excuse me. We saw this 13:52 happen in a compounding pharmacy uh gosh, it’s probably been 10 years ago 13:57 now, I think. um they unfortunately had a strep uh contamination in their 14:03 product and they weren’t testing it. It was a large compounding pharmacy out of Florida and they were making products 14:08 that were being injected into the joints and um these people got very very sick 14:14 and some of them died and um some of them got very very injured by this uh 14:21 complication that happened. So it’s not like this doesn’t happen. It does, but it doesn’t happen often. And that’s what 14:28 we have to know about. And so, when we’re talking with you guys about storage and stability, it’s really 14:34 important to make sure you maintain your peptides well. So, many peptides are unstable at room temperature. They 14:41 require refrigeration or freezing. We tell everyone to make sure you’re refrigerating your peptides. That way, 14:48 there’s no question about it. when it stays cold um it prevents or slows down 14:54 the process of uh bacteria growing in it. So some of these peptides actually 14:59 degrade very rapidly in the solution and they must be reconstituted immediately before use and reconstitution of the 15:07 peptides really has limited stability often just days to weeks not months. So 15:13 improper storage, temperature, um changes during shipping or prolonged 15:19 storage of a reconstituted product can lead to degradation into inactivity or 15:25 potentially even a harmful breakdown of the product itself. So if you have a product that’s been sitting in your 15:30 refrigerator for a month or two months or 3 months or 6 months, just throw it away. It’s not going to be any good. 15:37 you’re not going to actually get the peptide and the uh potency that you’re looking for anyway out of it and the 15:44 potential of you introducing an endotoxin, a bacterial endotoxin is quite high at that point. So you just 15:50 really don’t want to take the risk, excuse me. So what practitioners, what 15:56 should we do and what should patients do? Well, for any peptide therapy, we 16:03 want to source our verification. know where the peptide product comes from. Is 16:08 it an FDA approved product? Is it a 503b compounding? A research chemical 16:14 supplier? Is there a certificate of analysis? Request and review this COA. 16:20 And you want it to show purity greater than 95% but ideally greater than 98%. 16:27 You want that identity be identity to be confirmed by mass spectromedy. Uh 16:33 sterility testing should be done. Bacterial endotoxin testing should be done. Batch number matching of the 16:39 product that you received should be done. Proper storage. You want to know that this has been refrigerated or 16:46 frozen as directed once it’s been mixed. Look at the expiration dates for reconstituting your peptides. Track that 16:53 reconstitution date and discarded accordingly like we just talked about. Monitor for your adverse effects. Even 17:01 with the perfect quality control, monitoring for adverse effects is essential with questionable quality and 17:08 vigilance is really critical here. I know it’s frustrating for a lot of patients when they have to get several 17:15 bottles and they only last a week or two. right here, you guys. This is why 17:21 they only last a short period of time because once they’re mixed, they start 17:26 to degrade and they won’t be good and you won’t get the benefit from it. So, 17:31 it’s really important with these research peptides specifically, practitioners should recognize that all 17:38 recommending products without quality assurance violates the fundamental medical principle of first do no harm. 17:45 If a patient is determined to use research peptides despite counseling, providing guidance on quality 17:52 verification, requesting those COAs, using pharmaceutical grade sources when available, proper testing, this all 17:59 reduces harm, but doesn’t constitute necessarily that recommendation. Now, 18:06 that being said, today it’s very difficult to find peptides by the compoundingies because of what the FDA 18:13 has done. So most of the peptides that are available to us have been labeled 18:18 not for human consumption, not because they’re not good products, but because 18:25 of what the FDA did. And this is how these companies have been able to 18:31 continue to provide peptides to the medical community. And if you know you 18:36 have a good company, then you’re, you know, you’re still taking the risk, right? But at the end of the day, the 18:42 reason they’re doing that is to protect themselves from the FDA, from liability. Um, so just kind of know that there is 18:50 some talk in the community with um Bobby Kennedy that this is going to change and 18:55 they are going to bring peptides back to the compounding pharmacies. Now, we don’t know which ones they’re going to 19:01 bring back. Uh, will it be all of them? Will it just be some of them? What’s going to happen here? Um, is it going to 19:07 go to the pharmaceutical companies like our GLP1s did? We don’t know what that’s going to look like quite yet. Um, but it 19:14 is coming and that is positive news. So, let’s talk now about FDA approved 19:21 peptide medications. So, this is the metabolic revolution, right? GLP1 19:28 and our dual increeting agonists. This is an exciting time. GLP-1s are amazing. 19:35 Um, a lot of people are skeptical, a lot of people love them, a lot of people hate them. Whichever side of the fence 19:42 that you’re on, I understand. But I want to talk about the science of it today 19:48 and what it actually means for people. So, the story of GLP1 glucagon like 19:54 peptide one represents one of the most significant advances in metabolic 19:59 medicine in the past several decades. GLP-1 is an accretin hormone. It’s 20:05 gutder derived peptide that potentiates insulin secretion in response to food 20:11 intake. And the body naturally produces GLP-1 in the intestinal L cells, but it 20:17 rapidly degraded by the enzyme DPP4 giving it a halflife of only about 2 20:24 minutes. So this rapid breakdown made in therapeutically impractical until 20:31 research was developed and modified the analoges that resist the enzyme degradation. So for those people who 20:39 never feel full when they’re eating, never feel satisfied when they’re done, this is because their body is either not 20:46 producing enough GLP1 or it’s not getting the signal right. And this is a 20:51 leptin issue. This is an insulin issue. It’s a GLP-1 issue. It’s a complicated 20:56 issue. This is not anything that the person is doing wrong. It’s what is happening to their body. And so GLP1s 21:03 have really revolutionized this. So one particular GLP-1 that we have is 21:09 semiglutide. And this GLP-1 agonist is what changed everything in the world of 21:16 metabolic medicine. Semiglutide is marketed as ompic for type 2 diabetes 21:23 and it’s marketed as WGOI for chronic weight management. It is a modified 21:29 GLP-1 analog with 95 or sorry 94% amino acid sequence uh homology to human 21:37 GLP-1. So it means that it’s it’s just like our own GLP-1 that we make. This 21:42 modification includes specific amino acid substitutions and the addition of C18 21:50 a fatty acid chain which allows the peptide to bind to albumin. Now this 21:56 albumin binding dramatically extends the half-life to approximately one week 22:01 enabling one weekly dosing which is a major advantage over the earlier GLP-1 22:07 agonists that require daily or twice daily injections. The mechanism by which 22:13 semiglutide works is multiaceted. At the pancreatin level, it binds to GLP-1 22:20 receptors on the pancreatic beta cells enhancing glucose depending sorry 22:27 enhancing glucose dependent insulin secretion. This glucose dependency is 22:33 crucial. It means the peptide only stimulates insulin release when blood glucose is elevated. This dramatically 22:41 reduces the hypoglycemic risk compared to insulin or even uh sulfuras. 22:47 Simultaneously semiglutide suppresses glucagon secretion from pancreatic alpha 22:53 cells further improving glycemic control. This is really amazing because 23:00 over the years when we’ve used insulin, which is also a peptide by the way, you 23:05 had to dose it just right because if you didn’t, you would produce so much insulin that it would crash the blood 23:12 sugar and then somebody would have too low of a blood sugar. They’d be hypoglycemic and they’d have to eat more 23:18 sugar and then they’d have to modify the insulin again and the person would be going up and down, up and down, up and 23:24 down all day long. And that created a lot of problems for people and so this 23:30 helps to stabilize that so it is not such an intense change. Now in the GI 23:36 tract semiglutide delays the gastric emptying particularly pronounced during 23:41 the initial weeks of therapy. This slowing of the gastric emptying contributes to the sensation of being 23:48 full and early satiety that patients often describe. However, this effect 23:54 tends to attend to weight over time as the body adapts through the appetite 24:00 suppressing effects generally persist through central mechanisms. So, when we 24:05 talk about what is actually happening, we’re slowing that digestive process down. That’s why people aren’t so 24:11 hungry. It’s why they’re not eating so much. This is why people can develop constipation with these products because 24:17 it’s slowing the body’s digestive tract down. Now some people will call this 24:22 gastroparesis. Um gastroparesis is actually different. 24:28 It is when we lose control over what’s happening in the in the colon like the 24:34 nerves and things like that just stop working. I have never seen that with the GLP1s that we prescribe in micro doing. 24:42 um it’s been documented. It can happen, but again it a lot of it is dosing and a 24:48 lot of it is staying on top of your client and what’s happening and what’s going on and what you’re doing and making sure that they do have good 24:54 motility still. So a lot of these things can be mitigated if you have problems 24:59 with them. Now one of the most profound effects of semiglutide occur in the 25:05 central nervous system. GLP-1 receptors are widely distributed in the brain 25:10 particularly in the hypothalamus and the brain stem area where we are involved in 25:15 appetite regulation. So when when wilding and colleagues published their 25:20 landmark step one trial in the New England Journal of Medicine in 2021, 25:25 they demonstrated that participants receiving 2.4 4 milligrams of semiglutide weekly achieved an average 25:32 weight loss of 14.9% of their body weight over 68 weeks. Now, I want you 25:39 guys to really understand this. We’re talking roughly 15% body weight loss 25:45 over a year, longer than a year. 52 weeks is a year, right? This is 68 25:50 weeks. So, it took longer for them to lose. We’re not talking about giving 25:55 somebody a dose to lose 15% of their body mass in a month or two. That that 26:01 is not healthy for any of us. That is not what we’re talking about doing here. Now, they compared this to placebo and 26:08 the placebo was only 2.4%. So, that is a significant difference. 26:14 And even beyond the numbers, patients reported something very qualitatively different, a reduction in what’s now 26:21 called food noise. Everybody knows what food noise is. We’ve talked about this long before GLP1. It’s that craving. 26:28 It’s that part of your brain that just keeps thinking about I want to eat something. You know, that was actually 26:34 reduced and they didn’t expect to see that happen. Now, this refers to the constant mental preoccupation with food, 26:42 the intrusive thoughts about eating, the difficulty in feeling satisfied. Semi-glutide appears to appears to 26:49 modulate reward pathways in the misolyic system reducing hedonic eating and food 26:57 cravings. Now there are also great cardiovascular effects of semiglutide 27:02 that extend beyond weight loss. Uh the sustained six and select trials 27:07 demonstrated significant reductions in major adverse cardiovascular events uh 27:14 mace in high-risisk populations. The select trial published in 2023 showed 27:20 that semiglutide reduced cardiovascular death, non-fatal myioardial inffection 27:25 and non-fatal stroke by 20% in adults with overweight or obesity and 27:31 established cardiovascular disease but without diabetes. So this suggests that 27:37 mechanisms beyond glucose control and weight loss possibly including 27:42 anti-inflammatory effects, improvements in endothelial function and favorable 27:47 changes to lipid profiles. Now I will tell you the clients that I work with that are on GLP1, 27:53 they will tell you that their inflammation has been significantly reduced. We are also seeing really 28:00 amazing results in lipid profiles. um part of its weight loss, but there is a 28:06 component to this that is lowering the triglyceride levels because it’s related to sugar and how the body’s processing 28:11 it. And we’re seeing better profiles, less need for statins as a result of 28:17 that. If if you want to listen to my episode on statins, I have one on that. Uh they are not my favorite medication. 28:24 I think it’s overprescribed and overused um and not really affecting or 28:29 addressing the problem. So these things can really be helpful. There’s also some 28:34 uh ramblings going on with GLP-1s saying that they may be able to help with 28:40 addiction in the future because of where they’re finding it affecting the brain and how it affects the food noise and 28:47 the cravings that we have for food and the addiction for food. Could it potentially help with other addictions 28:53 down the road? We’ll have to wait and see on that one. So semiglutide’s FDA prescribing information also includes a 29:00 box uh boxed warning about thyroid sea cell tumors. So in rodent studies 29:06 semiglutide caused dose dependent and treatment duration dependent sea cell 29:12 tumors at clinically relevant exposures. So while it’s unknown whether or not 29:17 semiglutide causes uh thyroid cancer tumors in humans and the rodent thyroid biology 29:26 differs significantly from humans, the drug is contraindicated in patients with a personal or family history of 29:33 medillary thyroid carcinoma or in patients with multiple endocrine neopl neoplasia syndrome type two. it is 29:42 uh contraindicated for safety effects with that. Um I have seen endocrinologists okay GLP1s to be used 29:50 in patients who’ve had other forms of thyroid cancer just not the meillary 29:55 thyroid cancer. So there is possibility there. Now the most common side effects 30:00 are gastrointestinal. It’s nausea affects about 20 to 44% of patients 30:06 depending on the formulation with diarrhea, vomiting, constipation, abdominal pain, and also frequently 30:13 reported in clinical trials. I see this in my clinic, too, especially dose dependent. Um, and it happens early on 30:20 when you’re first starting the medication, but seems to settle out over time. The one that I would add to this 30:26 that I don’t think they have on here is an increase in acid reflux. We also see that quite often uh especially in people 30:33 who suffer with acid reflux to begin with. Now these effects are typically most 30:40 pronounced during the escalation and they like I said often improve over time 30:45 but more serious but less common adverse effects include acute pancreatitis. 30:51 The medication needs to be discontinued immediately if this is confirmed. You can see some diabetic retinopathy 30:57 complications in patients with pre-existing retinopathy and acute kidney injury. Um, this usually happens 31:05 secondarily to dehydration from the GI effects. There are some gallbladder disease um that can occur and people who 31:13 have a sensitive gallbladder will describe uh discomfort with that. I’ve 31:18 even seen some people who’ve had their gallbladder out on GLP1s at the higher doses complain of similar pain that they 31:25 used to have when their gallbladder was in. So, really important to just kind of monitor these symptoms and work closely 31:32 with somebody that understands them and can be on top of them quite quickly if this happens. Excuse me. From an 31:39 integrative medicine perspective, semiglutide really represents a powerful tool, but it’s not a standalone 31:46 solution. Remember, the medication addresses one aspect of the metabolic dysfunction, the signaling systems 31:53 controlling appetite and glucose homeostasis, but it doesn’t address the root cause that led to the metabolic 32:00 disease in the first place. Patients who rely solely on the medication without addressing the ultrarocessed food 32:07 consumption, the ccadian disruptions, the chronic stress, the sleep apnea, or 32:12 underlying hormonal imbalances often experience weight regain when the medication is discontinued. 32:20 The drug is also not a substitute for addressing the emotional and psychological drivers of eating 32:26 behavior, including the unresolved trauma that may manifest as emotional eating. I think this is really important 32:33 because we don’t address the trauma issue enough with clients and we need to 32:38 be looking at that. There is a huge trauma effect out there these days that is I don’t want to say leading to or 32:45 causing but it is definitely contributing to chronic illness and it’s not being talked about enough. So we 32:52 really need to be talking about this and addressing this trauma aspect. Now the next GLP that one that I want to talk 32:59 about is trespathide. This is a dual agonist. It takes center stage. It is my 33:05 favorite GLP one. Trisepatide is marketed as Mangjaro for type 2 diabetes 33:11 and Zepbound for chronic weight management and it represents the next 33:16 evolution in increantbased therapy. This is a dual agonist a 39 amino acid 33:23 synthetic peptide structurally based on the human glucose dependent insulin tropic peptide so GIP sequence but 33:31 modified to activate both the GIP receptors and the GLP1 receptors. So the 33:37 addition of the GI GIP agonism to the GLP1 agonism appears to create this 33:46 synergistic effect that goes beyond simply adding the two mechanisms together. So the GIP like GLP-1 is an 33:55 increant hormone secreted by what is called the K cells in response to nutrient intake. It enhances glucose 34:02 dependent insulin secretion but it also effects on atapost tissue metabolism 34:09 potentially improving the insulin sensitivity in fat cells and influencing 34:14 how the body stores and metabolizes fat. So some research suggests that GIP may 34:20 also have effects on energy expenditure though this remains an area of 34:26 investigation. So basically what we’re saying is this drug may actually help 34:32 people who are insulin resistant or insulin sensitive, not just somebody who 34:38 has problems with glucose control. So, this is super exciting because it opens 34:43 up the door for all of these people for decades that we’ve been trying to manage with insulin resistance and trying to 34:50 prevent diabetes and honestly most of the time have been unsuccessful 34:56 unless you can keep your diet at 50 grams of carbs or less a day, which is extremely difficult. Um, and take some 35:04 supplements that may or may not work and or take some metformin that may or may not help. this drug actually really 35:11opens that up and helps in that capacity. So there was a clinical trial 35:17 called the surmount clinical trial which demonstrated that trespathide produces 35:22 even more substantial weight loss than semiglutide. In the surerount one trial published by uh J tree I might have said 35:31 that wrong. I apologize if I slaughtered your name and colleagues in the New York England Journal of Medicine in 2022. 35:38 Participants receiving the highest dose of trespide, which is 15 milligrams, achieved an average weight loss of 20.9% 35:47 of their body weight over 72 weeks, compared to 3.1% with placebo. This 35:54 level of weight loss approaches what’s typically only seen in beriatric surgery. So, this is amazing because if 36:02 this medication works and we don’t have to do beriatric surgery, stomach stapling basically, um, oh my gosh, it’s 36:11 amazing. There are so many complications and risks that go with stomach stapling and the different procedures that they 36:17 do these days. People don’t absorb their nutrients properly. They have to do liquid nutrients. It’s very complicated. 36:24 It’s very challenging. Many of these people gain their weight back. Um, and 36:30 this procedure is not fun to go through. So, if we could change that and change 36:35 the lives of people who’ve really been struggling, it is amazing. And I will tell you that I have seen this work. I 36:42 have seen people lose 100 150 pounds on these medications over a year or two 36:50 period of time. It is definitely slower than beriatric surgery on some standpoints, but that is okay. You don’t 36:56 want that rapid weight loss. It’s not good for you. It’s not healthy for you. It doesn’t look well. You know, we want 37:03 to do this safely and effectively in the best way that we can possibly do that for you. Now, the adverse effect profile 37:10 is similar to semiglutide. It’s dominated by gastrointestinal effects. 37:15 Nausea, diarrhea, decreased appetite, vomiting, constipation. These were all commonly reported in the surmount 37:22 trials. And like semiglutide, tricepide carries a blackbox warning regarding the 37:27 thyroid sea cell tumors based on the rodent data and it shares the same contra indications in patients with a 37:34 family history of thyroid cancer and men too. So the mechanism behind why 37:40 tepatide often produces more substantial weight loss than GLP-1. The agonism 37:45 alone remains under investigation, but it may relate to the complimentary effects on the different aspects of 37:51 energy homeostasis or to GIP’s effects on atapost tissue and potentially on 37:58 central central nervous system pathways that GLP1 alone doesn’t fully address. 38:03 Now patients often report even more profound reductions in food noise with tricepide compared to GLP1 and uh sorry 38:12 GLP1 the agonists through this is anecdotal and hasn’t been regularly 38:17 quantified in quality studies. So I’ve done both uh personally and in my 38:22 practice. I really like trespide better than semiglutide. For me I had too many side effects with semiglutide. uh I had 38:30 less side effects with trespathide. I also plateaued on semiglutide which I 38:35 didn’t really care for. And with Tresepide, I haven’t plateaued and I’ve been able 38:42 to lose about 25 pounds in um a year and a half and I’ve been able to maintain 38:49 that. Um and I continued to use it because I do have a strong family history of cardiovascular disease. And 38:56 if this could help me so that I don’t follow my family lineage with cardiovascular disease, I am all for 39:03 trying to do that. I’ve watched too many of my family members suffer from this. I’ve lost my dad at a very young age. I 39:09 lost my grandfather at a young age to it. All of their brothers to this. And I don’t want to be that same person. So 39:16 that is why I chose to do that. And I think it’s really important for us to take a look at that and understand that. 39:24 Now, I know this has been a really long podcast and I don’t typically do podcasts this long. I have a whole host 39:31 of information on additional peptides. So, I’m going to break this up for you 39:36 guys and I’m going to do another episode and we’re going to pick up where we left off here with these peptides so that we 39:43 can actually start to dive into different peptides as well. So, check 39:48 out my next podcast show when we’re going to dive into the peptides that 39:54 talk about sexual wellness, immune function, and all the other cool things 39:59 that we can do with peptides. So until then, remember to like, share, and 40:04 subscribe. It really helps us get out to other people and share our information, 40:10 and join us for our next episode as we continue the talk about peptides. 40:15 Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and 40:21 information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its 40:28 management, or our partners. Each affiliate, sponsor, and partner is an 40:34 independent entity with its own perspectives. Today’s content is provided forformational and educational 40:40 purposes only and should not be considered specific advice, whether financial, medical, or legal. While we 40:48 strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique 40:56 circumstances. We encourage you to consult with a qualified professional to address your 41:01 individual needs. Your use of information from this broadcast is entirely at your own risk. By continuing 41:08 to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its 41:14 associates harmless from any claims or damages arising from the use of this 41:20 content. We may update this disclaimer at any time and changes will take effect 41:26 immediately upon posting or broadcast. Thank you for tuning in. We hope you 41:31 find this episode both insightful and thought-provoking. Listener discretion 41:36 is advised.The post Episode 256 – How Peptides Work, Benefits, and FDA-Approved vs Off-Label Use Explained first appeared on Let's Talk Wellness Now.

>>Join our FREE monthly Gut Health Webinar, so you can begin your Healing Journey.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://modernendocrinewellness.com/join-gut-health⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

This episode covers: • Microplastics Are Destroying Male Fertility and Metabolism New research is putting microplastics in a category most men still are not taking seriously: direct reproductive and hormone risk. A 2024 study detected microplastics in every human testicle examined, with polyethylene and PVC among the most common polymers. PVC is especially relevant because it's often tied to chemical additives that can disrupt endocrine signaling. The broader body of evidence points to micro- and nanoplastics crossing barriers like the blood–testis barrier, driving inflammation and oxidative stress in the testes, and showing associations with impaired sperm quality and hormone disruption. The longevity move here is reducing overall load: better water filtration, less plastic food contact, no heating food in plastic, fewer packaged foods, and taking indoor dust and air quality seriously, especially for men thinking about fertility now or hormone resilience over decades. • Sources: – Study (PubMed): https://pubmed.ncbi.nlm.nih.gov/38745431/ – Coverage: https://people.com/microplastics-in-every-human-testicle-infertility-8651215 • Fear of Aging Is Linked to Faster Biological Aging A new study ties aging anxiety to measurable acceleration in biological aging using DNA methylation clocks. People who reported more worry and negative beliefs about aging showed faster epigenetic aging signals, and the molecular differences clustered around stress and inflammatory pathways. In plain terms, chronic threat-mode thinking around aging maps onto biology that looks older on the clocks. For a longevity audience, this is a practical reminder that mental inputs affect physiological outputs. If your day-to-day mindset is constant pressure and decline narratives, that can show up downstream in stress biology and inflammatory tone. A smarter play is building a longevity framework around function, strength, purpose, and community, alongside the usual pillars like sleep, training, and metabolic health. • Source: https://medicalxpress.com/news/2026-02-older-links-health-faster-epigenetic.html • Additional source: https://www.nyu.edu/about/news-publications/news/2026/february/aging-anxiety.html • Retatrutide, the Triple-Agonist Weight-Loss Drug Pushing Bariatric-Level Results Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors, and the weight-loss numbers being reported are massive. In a 68-week study in people with obesity and knee osteoarthritis, the highest dose group averaged about 28.7% body-weight loss, along with meaningful improvements in knee pain and function. This is the next phase of incretin medicine: multi-agonist drugs that can move body weight by a quarter or more. For biohackers, the performance and longevity angle is implementation: preserving lean mass through resistance training, hitting protein targets, monitoring micronutrients, and building a maintenance plan that doesn't collapse the moment the drug stops. The upside is cardiometabolic risk reduction at scale. The key is running it with structure. • Sources: – Eli Lilly release: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average – Coverage: https://nypost.com/2026/02/18/health/people-dropped-out-of-retatrutide-trial-for-losing-too-much-weight/ – Background: https://news.harvard.edu/gazette/story/2026/02/whats-next-for-glp-1s/ • AI Can Predict 130 Diseases From a Single Night of Sleep Stanford's SleepFM project shows how much long-horizon health information is encoded in sleep. Researchers trained a foundation model on roughly 585,000 hours of clinical polysomnography data from about 65,000 people. From a single night of sleep study signals, the model could estimate risk for 130 conditions, including dementia, heart attack, heart failure, chronic kidney disease, stroke, atrial fibrillation, and all-cause mortality, and it generalized across cohorts better than simple demographic baselines. The big implication is that sleep architecture and micro-patterns (stage distribution, fragmentation, breathing stability, micro-arousals) function like a dense biomarker stream for systemic aging and disease risk. Expect better sensors and more validated risk dashboards over time. Right now, this is another reason to treat sleep as a core diagnostic pillar, not just a recovery habit. • Sources: – Stanford Medicine: https://med.stanford.edu/news/all-news/2026/01/ai-sleep-disease.html – Paper (Nature Medicine): https://www.nature.com/articles/s41591-025-04133-4 • Living at High Altitude May Protect Against Diabetes by Turning Red Blood Cells Into Glucose Sinks For years, population data has suggested lower diabetes rates at higher elevations. New mechanistic work is pointing to a surprising driver: red blood cells changing how they handle glucose under low oxygen conditions. In hypoxia, red blood cells can behave like glucose sinks, pulling more sugar out of circulation and improving glucose tolerance, which may help explain the protective association seen at altitude. The downstream potential is a new class of altitude-mimetic approaches that target erythrocyte metabolism as a glucose lever, separate from appetite suppression or classic diabetes pathways. For biohackers, it expands the metabolic toolkit and reinforces that oxygen environment and blood physiology matter more than we've given them credit for. • Source: https://medicalxpress.com/news/2026-02-red-blood-cells-sugar-high.html • Dietary Supplement Regulatory Uniformity Act and the Future of Supplement Access A proposed bill is aiming to stop states from layering extra rules on dietary supplements beyond federal law, creating one national standard instead of a patchwork of state-by-state restrictions. Industry groups are supporting it as a way to reduce confusion and compliance chaos, especially as some states explore age limits or special labeling requirements for certain supplement categories. The strategic implication for biohackers is that regulation shapes access. Uniformity can stabilize availability, but it also raises the stakes of federal decisions on controversial ingredients. This is one of those policy stories that quietly determines what stays on shelves, what disappears, and how much innovation survives in the supplement space. • Sources: – NutritionInsight: https://www.nutritioninsight.com/news/npa-crn-supplements-us-fda-legislation.html – Congressional release: https://langworthy.house.gov/media/press-releases/congressman-langworthy-introduces-dietary-supplement-regulatory-uniformity-act – NutraIngredients: https://www.nutraingredients.com/Article/2026/02/05/new-bill-aims-to-end-state-supplement-regulations/ All source links are provided for direct access to the original reporting and research. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: microplastics male fertility, microplastics testosterone decline, blood–testis barrier toxins, endocrine disruption plastics, sperm count microplastics, epigenetic age acceleration, fear of aging methylation, biological aging mindset, stress inflammation aging, retatrutide triple agonist, GLP-1 GIP glucagon weight loss, incretin drugs obesity treatment, muscle preservation on GLP-1, SleepFM AI model, sleep disease prediction, polysomnography risk scoring, dementia risk sleep data, altitude diabetes protection, hypoxia glucose metabolism, red blood cells glucose uptake, altitude mimetic therapy, Dietary Supplement Regulatory Uniformity Act, supplement regulation federal preemption, FDA supplement policy, biohacking news longevity, metabolic health optimization Thank you to our sponsors! - HeartMath | Go to https://www.heartmath.com/dave to save 15% off. - BrainTap | Go to http://braintap.com/dave to get $100 off the BrainTap Power Bundle. Resources: • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 – Intro 0:19 – Story 1: Microplastics in Testicles 1:44 – Story 2: Fear of Aging Accelerates Aging 3:30 – Story 3: Retatrutide Weight Loss Drug 4:42 – Story 4: Sleep Predicts Disease Risk 6:34 – Story 5: High Altitude & Diabetes 7:57 – Story 6: Supplement Regulation Bill 9:16 – Weekly Summary 10:51 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send a textWe break down the mechanism of action for GLP-1 receptor agonists like tirzepatide (Zepbound/Mounjaro) and semaglutide, explaining how these medications work in the body to regulate appetite and metabolism.• GLP-1 medications contain a C20 fatty diacid that binds to albumin, prolonging half-life• These drugs target both GIP and GLP-1 receptors to regulate appetite and caloric intake• Receptors are found in brain areas involved in appetite regulation and throughout the GI system• Pharmacodynamics include increased insulin sensitivity, reduced glucagon secretion, and delayed gastric emptying• Medications are absorbed subcutaneously with about 80% bioavailability • Distribution occurs throughout the body with 5-6 day half-life, explaining weekly dosing• Metabolism occurs primarily through the liver with excretion via urine• Common injection sites include arms, legs, stomach, or back (the "margarita" zones)Never do this on your own without real supervision. Everything has to be done safely, with a healthcare provider and someone that is aware of where you stand and how you are. Support the show Sponsor Affiliates Empowering Your Health https://www.atecam.com/ Get YOUR Own Joburg Protein Snacks Discount Code: Damaris15 Or Damaris18 Feeling need to Lose Weight & Become metabolically Healthy GET METABOLIC COURSE GLP 1 REseT This course is designed for individuals looking to optimize their metabolic health through integrative and functional medicine approaches. Whether you're on a GLP-1 medication or seeking natural ways to enhance your metabolic function, this course provides actionable steps, expert insights, and a personalized roadmap sustainable wellness. Are you feeling stressed, tired, or Metabolism imbalanced? Take advantage of our free mindful steps to help improve your well-being.ENJOY ONE OF our Books Mindful Ways Health Wealth & Life https://stan.store/Mindfullyintegrative Join Yearly membership ALL IN ONE FUNCTION HEALTH Ask Us for help...

Het begin van Gip's Big Year moest en zou natuurlijk in het Vondelpark zijn. Weet je het nog, de eerste stapjes, Gisbert nog zo groen als gras en als doelsoort de grote bonte specht. Maar ook de halsbandparkiet, de meerkoet en verschillende andere vogels passeerde toen de revue. Nu zal het vast niet anders gaan, maar met het enige verschil dat Arjan ze niet mag aanwijzen. En de doelsoort is ook veranderd en wel een hele bijzondere soort, namelijk Ronnie. Het zal de fanatieke vogelaar niet ontgaan zijn, maar afgelopen winter huist er een roerdomp in het park en laat dat nou ook de lievelingsvogel van Gip zijn. Dus als de cirkel nu niet rond is, weten we het ook niet meer.Partnerships:Vogelbescherming Nederland - Wil je een gratis magazine uit de aflevering? Ga dan naar vogelbescherming.nl/tijdschrift en meld je aan.Vivara - Meer vogels in je tuin? Koop dan nu vogelvoer en vogelhuisjes van onze eigen vogelspotcastlijn en voor je het weet zit je tuin vol vogels. Check vivara.nl/vogelspotcast voor het assortimentSNP - Wil je mee met Arjan en Gip naar Cyprus in september. Wees er dan snel bij. Ga naar SNP CyprusDwaalgasten - Lid worden van de leukste vogelcommunity van Nederland? Word lid van de dwaalgasten via Petje AfLuistervinken - Wil je niks missen van Gip's Big Year? Luister dan ook de extra afleveringen via Petje AfZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

What if the goal wasn't just to lose weight, but to achieve a balanced "weight health ecosystem"? In this episode, I speak with Ashley Koff about how ultra-processed foods, under-fueling, and disrupted hormones have shaped today's metabolic crisis—and why weight loss alone is the wrong goal. Ashley shares her deeply personal journey and her science-backed framework for understanding weight health, including a clear, honest conversation about GLP-1 medications and how to use them responsibly. Ashley Koff, RD, is the USA Today bestselling author of Your Best Shot (HarperOne) and founder of The Better Nutrition Program (BNP). With over twenty-five years of experience, Ashley's helped redefine how we approach sustainable, lasting weight health. In her new book, Your Best Shot, Ashley introduces weight-health hormones (GLP-1, GIP, CCK, PYY) and offers the first-ever system for assessing and optimizing these hormones, whether you're using GLP-1 medication or not. It's a game-changer for anyone who's felt stuck, blamed themselves, or been failed by traditional dieting. What you'll learn: (02:10) Why ultra-processed foods undermine satiety and metabolic health. (08:05) How dieting and under-fueling can damage digestion, hormones, and muscle. (13:40) What “weight health” means and why weight alone misses the real problem. (15:30) How GLP-1 and other incretin hormones regulate appetite, fat storage, bone, and metabolism. (17:45) Why enriched and ultra-processed foods leave the body under-resourced. (21:00) How GLP-1 medications work differently from the body's natural hormone signals. (24:10) Why fatigue, digestive issues, and muscle loss can happen on GLP-1s when dosing and nutrition aren't optimized. (30:20) Whether it's possible to come off GLP-1 medications and what sustainable success actually looks like. Love the podcast? Here's what to do: Subscribe to the podcast. Leave a review. Text a screenshot to me at 813-565-2627 and wait for a personal reply because your voice is so important to me. Want to listen to the show completely ad-free? Go to http://subscribetojj.com Click “TRY FREE” and start your ad-free journey today! When you're ready, enjoy the VIP experience for just $4.99 per month or $49.99 per year (save 17%!) Full show notes (including all links mentioned): https://jjvirgin.com/yourbestshot Learn more about your ad choices. Visit megaphone.fm/adchoices

Beginnen bij het begin. We doen als mens niet anders. Soms is het goed om een stapje terug nemen, om alles weer even op een rijtje te zetten en te herijken. Maar natuurlijk begin je niet zoals je ooit begon. Je bent heb ondertussen een hoop dingen meegemaakt, hebt fouten gemaakt, gelachen, gehuild en vast veel geleerd. Zo ook Gip. Ruim vijf jaar geleden zijn we met de Vogelspotcast begonnen en hebben de jongens meer dan 270 soorten gezien en vele avonturen meegemaakt. Maar toch knaagt er iets. Gip is er achter gekomen dat hij nog niet echt zelfstandig kan vogelen. In de figuurlijke zijspan aangehaakt bij Arjan is er enorm veel gezien en gehoord, maar echt zelf ontdekt niet echt. Dus hebben we besloten het roer om te gooien. Het is tijd dat Gip zelfstandig gaat vogelen en een eigen lijst begint. En daar heeft Arjan het perfecte plan voor... Benieuwd? Luister de eerste podcast waar we tegen alle tradities in een indoor podcast maken. Want tja, plannen maak je toch aan de tekentafel. Deze podcast is mede mogelijk gemaakt door: Vogelbescherming Nederland - Wil je een gratis magazine uit de aflevering? Ga dan naar vogelbescherming.nl/tijdschrift en meld je aan.Vivara - Meer vogels in je tuin? Koop dan nu vogelvoer en vogelhuisjes van onze eigen vogelspotcastlijn en voor je het weet zit je tuin vol vogels. Check vivara.nl/vogelspotcast voor het assortimentSprinkl - Wil jij ook een mooie haag in de tuin waar alle vogels op af komen? Bestel deze dan nu bij sprinklr.co/products/tuiny-haag en krijg het 4 maart geleverd. SNP - Wil je mee met Arjan en Gip naar Cyprus in september. Wees er dan snel bij. Ga naar SNP Cyprus Dwaalgasten - Lid worden van de leukste vogelcommunity van Nederland? Word lid van de dwaalgasten via Petje Af Luistervinken - Wil je niks missen van Gip's Big Year? Luister dan ook de extra afleveringen via Petje Af Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

As canetas emagrecedoras causam queda de cabelo?A resposta não é simplista.Os agonistas de GLP-1 e GLP-1/GIP não “atacam” diretamente o folículo. Eles reduzem apetite e podem induzir perda rápida de peso. O que pode ocorrer, se não houver estratégia nutricional adequada, é a instalação de um ambiente metabólico menos anabólico.O folículo piloso é um dos tecidos mais metabolicamente ativos do corpo humano. Ele depende de sinalização via IGF-1 e da via mTOR para manter proliferação da matriz e espessura do fio. Redução de ingestão proteica, perda de massa magra e balanço nitrogenado negativo podem diminuir essa sinalização e favorecer encurtamento da fase anágena e afinamento progressivo — especialmente em quem já apresenta alopecia androgenética.Isso não é novo.Estudos das décadas de 60 e 70 já demonstravam que restrição proteico-calórica alterava rapidamente a morfologia do bulbo capilar, reduzindo seu diâmetro e sua atividade proliferativa — muitas vezes antes de alterações laboratoriais clássicas.O passado não é ultrapassado.É bússola.Se você está utilizando agonistas de GLP-1, conduza o emagrecimento com estratégia metabólica.Se você trata alopecia androgenética, entenda que o terreno anabólico influencia diretamente o resultado terapêutico.O folículo responde à biologia.Agende sua avaliação no link da descrição.SEU TRATAMENTO É O SEU MELHOR PARCEIRO PARA O SUCESSO CAPILAR.

If you hit menopause and suddenly feel like your metabolism has slammedon the brakes, you're not alone—and you're not failing! In this episode, we unpack why weight gain after menopause is so stubborn and why “eat less, move more” often stops working altogether!We dive into the emerging science behind hormone replacement therapy (HRT) and tirzepatide, a next-generation GLP-1/GIP medication, and how they may work together to address the hormonal and metabolic shifts driving midlife weight gain. We also explore where thyroid health fits into the picture—and why ignoring it can sabotage your results.This is a must-listen for anyone curious about smarter, more personalized approaches to weight loss after menopause. Expect evidence-based insights, clear explanations, and empowering takeaways to help you decide what options actually make sense for your body—now and moving forward.

Geotechnical & Geo-environmental Career Support If you're exploring your next role - or trying to solve a hiring bottleneck - I offer confidential advice to professionals and firms across the geotechnical and geo-environmental sector. Book a free, confidential career or hiring call:

Send us a textWhat gets measured shapes how patients experience the final chapter of life.  In Part Two of Measures That Matter: How Better Metrics Can Transform End-Of-Life Care, hospice and healthcare leaders explore how focused, meaningful metrics—not check-the-box measures—can improve quality, reduce unnecessary hospitalizations, and strengthen value-based end-of-life care.Hosted by Chris Comeaux, President & CEO of Teleios, and Cordt Kassner, PhD, Publisher of Hospice & Palliative Care Today and CEO & Founder of Hospice Analytics, this episode brings together national experts to examine which hospice measures truly differentiate quality.Featured guestsBob Tavares, VP & General Manager, HealthPivotsRobin Heffernan, PhD, Co-Founder & CEO, EmpassionMindy Stewart-Coffee, National Vice President, Palliative Care, Optum Home & CommunityThe conversation highlights a small, high-impact set of indicators that better reflect real-world hospice performance—such as visits in the last days of life, live discharges and burdensome transitions, gaps in nursing visits, access to higher levels of care (GIP and Continuous Home Care), and patient experience, including the simple but powerful question: “Would you recommend this hospice?”A central takeaway is nuance: more is not always better. High-quality hospice care lives within healthy ranges and must be interpreted in clinical, geographic, and population context—not through rigid or one-size-fits-all targets.The episode also highlights the critical role of palliative care upstream from hospice. Earlier, multidisciplinary engagement helps align goals, manage symptoms proactively, and reduce crises and late referrals—ultimately redefining value at the end of life as goal-concordant care delivered at the right time, in the right setting, at a sustainable cost. Hospice and palliative care are not peripheral to value-based healthcare—they are foundational to it.Great end-of-life care isn't accidental—it's designed, supported, and measured well.The Anatomy of Leadership podcast explores the art and science of leadership through candid, insightful conversations with thought leaders, innovators, and change-makers from a variety of industries. Hosted by Chris Comeaux, each episode dives into the mindsets, habits, and strategies that empower leaders to thrive in complex, fast-changing environments. With topics ranging from organizational culture and emotional intelligence to navigating disruption and inspiring teams, the show blends real-world stories with practical takeaways. The goal is simple yet ambitious: to equip leaders at every level with the tools, perspectives, and inspiration they need to lead with vision, empathy, and impact. https://www.teleioscn.org/anatomy-of-leadership

What gets measured shapes how patients experience the final chapter of life.  In Part Two of Measures That Matter: How Better Metrics Can Transform End-Of-Life Care, hospice and healthcare leaders explore how focused, meaningful metrics—not check-the-box measures—can improve quality, reduce unnecessary hospitalizations, and strengthen value-based end-of-life care.Hosted by Chris Comeaux, President & CEO of Teleios, and Cordt Kassner, PhD, Publisher of Hospice & Palliative Care Today and CEO & Founder of Hospice Analytics, this episode brings together national experts to examine which hospice measures truly differentiate quality.Featured guestsBob Tavares, VP & General Manager, HealthPivotsRobin Heffernan, PhD, Co-Founder & CEO, EmpassionMindy Stewart-Coffee, National Vice President, Palliative Care, Optum Home & CommunityThe conversation highlights a small, high-impact set of indicators that better reflect real-world hospice performance—such as visits in the last days of life, live discharges and burdensome transitions, gaps in nursing visits, access to higher levels of care (GIP and Continuous Home Care), and patient experience, including the simple but powerful question: “Would you recommend this hospice?”A central takeaway is nuance: more is not always better. High-quality hospice care lives within healthy ranges and must be interpreted in clinical, geographic, and population context—not through rigid or one-size-fits-all targets.The episode also highlights the critical role of palliative care upstream from hospice.  Earlier, multidisciplinary engagement helps align goals, manage symptoms proactively, and reduce crises and late referrals—ultimately redefining value at the end of life as goal-concordant care delivered at the right time, in the right setting, at a sustainable cost.  Hospice and palliative care are not peripheral to value-based healthcare—they are foundational to it.Great end-of-life care isn't accidental—it's designed, supported, and measured well.Teleios Collaborative Network / https://www.teleioscn.org/tcntalkspodcast

Send us a textThis week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant announcements and strategic initiatives that are shaping the landscape of drug development and patient care.Starting with a notable investment move, Eli Lilly has announced a $3.5 billion manufacturing facility in Pennsylvania, marking a significant milestone in their "Lilly in America" initiative. This facility is set to focus on injectables and devices, reinforcing Lilly's dedication to expanding its manufacturing capabilities within the United States. These types of investments are increasingly crucial as they aim to enhance supply chain resilience and support the production of complex biologics and innovative therapies—a step that could prove pivotal in maintaining a competitive edge in the global pharmaceutical market.Meanwhile, Regeneron's Eylea franchise is encountering challenges with declining sales, even with the introduction of Eylea HD. This situation highlights the difficulties companies face in maintaining market share amidst fierce competition and evolving treatment paradigms in ophthalmology. It underscores the importance of continuous innovation and effective lifecycle management strategies to sustain product competitiveness in a rapidly changing industry environment.Takeda is also navigating turbulent waters with its ADHD medication Vyvanse facing generic competition. Despite this, Takeda maintains an optimistic outlook for future growth by narrowing the revenue gap between declining Vyvanse sales and contributions from new products. This transition is reflective of a broader industry trend where companies pivot towards novel therapeutics to offset revenue losses from patent expirations, exemplifying strategic adaptation in response to market dynamics.AstraZeneca's ambitious $18.5 billion obesity deal with China's CSPC exemplifies the growing focus on metabolic disorders driven by rising global obesity rates. This partnership not only reinforces AstraZeneca's expansion strategy into China but also highlights the increasing importance of addressing obesity—a major public health challenge with significant healthcare cost implications. The deal marks a strategic push to leverage advanced therapeutic approaches, particularly targeting GLP-1 and GIP receptors with long-acting dual agonists. Additionally, AstraZeneca's further $15 billion pledge for investments in Chinese cell therapies and radiopharmaceuticals is expected to enhance its capabilities in personalized medicine and expand its global presence across key therapeutic areas—a reflection of a broader industry trend towards asset-centric deals prioritizing targeted acquisitions over traditional mergers.Novo Nordisk's ongoing legal challenge against drug pricing provisions in the Inflation Reduction Act (IRA) is gaining momentum, with support from the U.S. Chamber of Commerce urging the Supreme Court to review the case. This legal battle underscores ongoing tensions between pharmaceutical companies and regulatory frameworks aimed at controlling drug prices, reflecting broader debates on healthcare affordability and access—a critical issue that continues to shape policy discussions across the industry.Across the Atlantic, CDMO Vetter's €480 million investment in a new plant in Germany signals robust growth in contract development and manufacturing services. This expansion aligns with increasing demand for outsourcing solutions in biopharmaceutical production, driven by complex manufacturing processes and capacity constraints faced by many biotech firms. Such investments are pivotal as they aim to enhance production capabilities and meet growing demands for innovative biologics.Quince Therapeutics recently experienced a setback with its steroid delivery technology for ataxia-telangiectasia, illustrating the Support the show

„Die Abnehmspritze verbrennt kein Fett. Sie verändert unser Essverhalten – über das Gehirn.“ – Abnehmspritzen wie Wegovy und Ozempic (Semaglutid) oder Mounjaro (Tirzepatid) zählen aktuell zu den wirksamsten Medikamenten zur Gewichtsreduktion bei Adipositas. Die Wirkstoffe imitieren körpereigene Darmhormone wie GLP-1 und GIP, beeinflussen Appetit, Sättigung und Stoffwechsel und führen bei vielen Betroffenen zu einem Gewichtsverlust von 15 bis 20 Prozent oder mehr. Mit zeitlichem Abstand zum ersten Hype liegt heute eine deutlich bessere Datenlage vor. Und die zeigt: Die Abnehmspritze ist hochwirksam – aber komplexer, als frühe Schlagzeilen vermuten ließen. Wissenschaftliche Updates deuten neben der Gewichtsreduktion auch auf positive Effekte bei Herz-Kreislauf-Erkrankungen hin, etwa eine Senkung des Risikos für Herzinfarkt und Schlaganfall. Auch mögliche Zusammenhänge mit einem reduzierten Demenzrisiko werden aktuell intensiv erforscht. Gleichzeitig ist klar: Die Wirkung ist meist nicht dauerhaft, wenn die Medikation beendet wird. Nach dem Absetzen kommt es bei vielen Menschen zu einer raschen Gewichtszunahme. Genau deshalb wird die Abnehmspritze heute zunehmend als Teil einer langfristigen Therapie eingeordnet – kombiniert mit Ernährung, Bewegung und strukturellen Lebensstilveränderungen. In dieser Episode der artgerecht HEALTH NERDS liefern Podcast-Host Felix Moese und Gesundheitswissenschaftler Matthias Baum ein umfassendes Update zur Abnehmspritze. Ursprünglich stammen die Wirkstoffe aus der Diabetes-Therapie – neu ist, dass sie heute auch offiziell bei Adipositas als medizinische Option eingesetzt werden. Klar wird dabei: Die Spritze ist kein Lifestyle-Shortcut, sondern – wenn überhaupt – ein therapeutisches Werkzeug mit klarer medizinischer Indikation. Ein weiterer Fokus liegt auf der Qualität des Gewichtsverlusts. Aktuelle Studien zeigen: Ein relevanter Teil des verlorenen Gewichts stammt aus der fettfreien Masse, also aus Muskulatur. Vor allem bei älteren Menschen kann das problematisch werden, wenn Ernährung und Bewegung nicht gezielt gegensteuern. Wir schauen außerdem auf Nebenwirkungen, zu denen es heute deutlich belastbarere Daten gibt als noch vor wenigen Jahren: von Übelkeit und Verdauungsproblemen bis hin zu seltenen, aber relevanten Risiken. Und wir ordnen ein, was an Berichten über Augenprobleme oder Suizidalität wissenschaftlich belegt ist – und was nicht. Zum Schluss werfen wir den Blick nach vorn: An welchen neuen Wirkstoffen wird aktuell geforscht? Wie realistisch sind Medikamente, die nicht mehr wöchentlich, sondern nur einmal im Jahr angewendet werden müssen? Und welche positiven Effekte zeigen sich bereits heute – etwa beim Thema Schlafapnoe? Matthias beantwortet außerdem die entscheidende Frage: Für wen ist die Abnehmspritze heute medizinisch sinnvoll – und für wen ganz klar nicht? HEALTH NERDS. Mensch, einfach erklärt. Ein ALL EARS ON YOU Original Podcast.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a landscape marked by dynamic shifts and groundbreaking advancements in the industry.The European Union has recently taken a significant step forward by eliminating pharmaceutical export tariffs through a comprehensive free trade agreement with India. This landmark deal, nearly two decades in the making, is a strategic response to the turbulence in global markets. By potentially enhancing market access and reducing costs for drug manufacturers involved in transcontinental trade, this agreement sets a precedent for future international trade negotiations. It could also catalyze more collaborations in drug development and distribution, offering a template for how regions can work together to streamline pharmaceutical trade.Siegfried has made headlines by extending its mergers and acquisitions streak, acquiring three sites from SK Capital as part of its U.S. onshoring strategy. The acquisition of active pharmaceutical ingredient sites in Delaware, Georgia, and Australia is aimed at boosting production capabilities while reducing supply chain vulnerabilities. This move aligns with broader industry trends that emphasize geographical diversification and supply chain resilience, reflecting the industry's ongoing adaptation to global economic pressures.Meanwhile, China's National Medical Products Administration has suspended sales of Sun Pharma's dementia medication following site inspections that revealed manufacturing deficiencies. This regulatory action underscores the critical importance of compliance with stringent manufacturing standards and highlights the potential repercussions of lapses in quality control. It also demonstrates the increasing scrutiny from regulatory bodies worldwide to ensure drug safety and efficacy.On the clinical front, Roche has reported promising results for its dual GLP-1/GIP receptor agonist, showing a 22.5% weight loss at 48 weeks. This development is significant given the rising global demand for effective weight management therapies amid increasing obesity rates. The progression of this asset into phase 3 trials could herald a new class of therapeutics with substantial implications for patient care.In another strategic shift, Catalent has decided to wind down operations at its EU cell therapy manufacturing hub, reflecting a reassessment of facility utilization amidst changing market demands. This move is indicative of broader industry adjustments as companies streamline operations to focus on core competencies and emerging therapeutic areas.Turning to promising new therapies, United Therapeutics' bioengineered external liver assist system has shown potential in treating acute chronic liver failure based on early phase 1 trial results. Innovations like these highlight the transformative potential of bioengineering in addressing unmet medical needs and improving patient outcomes.Boehringer Ingelheim's significant investment in Simcere's preclinical bispecific antibody for inflammatory bowel disease underscores the industry's commitment to advancing novel therapeutic modalities. This EUR 1.05 billion deal reflects confidence in biologic therapies as essential components in managing complex chronic diseases.As we look towards 2026, biopharma companies are strategizing long-term amid evolving rules and heightened stakes. The sector is poised for transformation driven by scientific breakthroughs, regulatory challenges, and strategic alliances that promise enhanced patient care through innovative therapies. These developments reflect an industry that remains agile and resilient as it navigates complex global landscapes.In other news, Qilu Pharmaceutical's $120 million alliance with Insilico Medicine marks a significant step towards leveraging artificial intelligence (AI) for drug discSupport the show

Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. These numbers appear to put CT-388, which Roche acquired in its $2.7 billion Carmot buy, in line with Eli Lilly's Zepbound, according to William Blair analysts. Roche plans to start a Phase III study of CT-388 in the first half of this year and is also pairing the drug with a therapy from Zealand Pharma, with the aim of offering a weight lossoption with fewer gastrointestinal side effects. Meanwhile, Baseline Therapeutics debuted to challenge Lilly with a Phase III–ready GLP-1 for alcohol use disorder.  In the vaccines sector, Moderna took perhaps the biggest action to date amid Health Secretary Robert F. Kennedy's anti-vaccine policies and rhetoric, last week announcing that the company will no longer run late-stage vaccine trials for infectious diseases. “You cannot make a return on investment if you don't have access to the U.S. market,” CEO Stéphane Bancel saidthe World Economic Forum at Davos, Switzerland. Pfizer CEO Albert Bourla, also speaking at Davos, called RFK Jr.'s rhetoric and policies on vaccines “anti-science.”  Finally, Sarepta released new data on Monday for Elevidys, the company's embattled gene therapy for neuromuscular disease Duchenne muscular dystrophy. Plus, check out up-and-coming treatments for Alzheimer's and Parkinson's.

This episode covers: • Real Food Reset in U.S. Dietary Policy The new Dietary Guidelines for Americans 2025–2030 put real food back at the center of U.S. nutrition policy and take a direct swing at ultra processed foods, added sugar, and sugary drinks. Dave breaks down why this matters beyond personal dieting: these guidelines influence school meals, SNAP and WIC, federal feeding programs, and they shape what eventually shows up on labels and in public institutions. He also shares how biohackers can use this shift as leverage to push for better food environments in schools, workplaces, and hospitals. -Source: https://www.usda.gov/about-usda/news/press-releases/2026/01/07/kennedy-rollins-unveil-historic-reset-us-nutrition-policy-put-real-food-back-center-health • Drug Combo Extends Lifespan of Frail Old Mice by 73% A new aging study found that combining oxytocin with a compound called A5i extended the remaining lifespan of frail elderly male mice by 73%, while also improving function and tissue health. Dave explains why this is a big signal for the future of longevity medicine: stacking targeted interventions can outperform single compounds, especially when you start late in life. He also explains what to do with the idea right now: stop building random “everything stacks” and start thinking in phases, tracking outcomes, and waiting for real human combo data. -Source: https://www.futura-sciences.com/en/study-finds-drug-combo-could-slow-aging-and-increase-lifespan-by-73_23229/ • ChatGPT Health Turns Your Data Into a Health OS OpenAI launched ChatGPT Health, a dedicated health experience that lets you securely connect medical records and wellness apps like Apple Health and MyFitnessPal, so you can summarize visits, interpret labs, and prepare better questions for your doctor. Dave explains why this is a turning point for quantified self and protocol building: it reduces the friction of pulling data from five different places, and it makes pattern-finding accessible to nontechnical people. He also shares how to use it like a pro: clean inputs, smarter questions, and better doctor conversations. -Source: https://openai.com/index/introducing-chatgpt-health/ • Whole Milk Is Back in Schools The Whole Milk for Healthy Kids Act restores whole and reduced-fat milk options in schools, aligning school nutrition rules with the updated dietary guidelines that no longer treat full-fat dairy like a default villain. Dave breaks down why this matters for child healthspan: satiety and nutrient density drive behavior, learning, and metabolic stability. He also explains why this is a real-world policy experiment worth watching across school districts, and how it can open the door for bigger institutional upgrades like better protein and fewer ultra processed items. -Source: https://www.usda.gov/about-usda/news/press-releases/2026/01/14/whole-milk-back-president-trump-signs-whole-milk-healthy-kids-act • Tirzepatide Trial Targets Biological Age With Aging Clocks A registered clinical trial titled Tirzepatide to Slow Biological Aging is using multiple DNA methylation aging clocks as primary endpoints, along with functional metrics like grip strength and a 6-minute walk test. Dave explains why this is a big maturity step for longevity science: instead of assuming metabolic improvement equals slower aging, this study is measuring biological age directly, across multiple clocks, with performance outcomes. He also shares the practical lesson for biohackers: stop relying on one favorite metric and start thinking in panels, function, and durability of results. -Source: https://clinicaltrials.gov/study/NCT07220473 All source links provided for direct access to the original research and reporting. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want practical strategies rooted in cutting-edge science. Host Dave Asprey translates emerging research into actionable upgrades for your biology, from metabolism and food policy to AI-driven tracking, institutional nutrition, and biological aging measurement. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Dietary Guidelines for Americans 2025-2030, real food policy reset, ultra processed foods policy, added sugar limits, sugary drinks guidelines, school lunch nutrition policy, SNAP WIC nutrition impact, USDA HHS dietary guidelines 2026, whole food protein guidelines, full fat dairy guidelines, oxytocin aging study, A5i lifespan extension, frail elderly mice lifespan 73 percent, combination longevity therapies, aging intervention synergy, staged longevity protocols, functional aging biomarkers, ChatGPT Health launch, OpenAI health records AI, Apple Health ChatGPT integration, MyFitnessPal ChatGPT integration, AI lab interpretation, AI doctor visit summary, quantified self AI tools, Whole Milk for Healthy Kids Act, whole milk back in schools, school dairy policy change, child satiety nutrition, school meal regulations USDA, tirzepatide biological aging trial, GLP-1 GIP longevity, epigenetic aging clocks trial, DNAmAge PhenoAge GrimAge DunedinPACE, grip strength aging endpoint, 6 minute walk aging endpoint, biological age measurement, longevity clinical trial endpoints, biohacking news update, longevity policy shifts, metabolic health upgrades Thank you to our sponsors! -BEYOND Conference 2026 | Register now at https://beyondconference.com/ -EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE for 40% off Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps:0:00 - Intro0:19 - New Dietary Guidelines2:09 - Longevity Research Breakthrough3:41 - ChatGPT Health Launch5:10 - Whole Milk Returns to Schools6:29 - GLP-1 Aging Trial7:34 - Weekly Upgrade Protocol9:09 - OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Geotechnical & Geo-environmental Career Support If you're exploring your next role - or trying to solve a hiring bottleneck - I offer confidential advice to professionals and firms across the geotechnical and geo-environmental sector. Book a free, confidential career or hiring call:

Amber Warren, PA-C, is joined by functional medicine nurse practitioner Heather Lucas, MSN, FNP-C, to explain the science behind GLP-1–based therapies and metabolic weight loss. They break down how GLP-1, GIP, and glucagon influence appetite, insulin resistance, and fat metabolism, and discuss how therapies such as semaglutide, tirzepatide, and emerging triple agonists are used in metabolic care.This episode explores why improving metabolic health requires more than appetite suppression, highlighting the role of nutrition, strength training, sleep, stress, and gut health. Learn how peptides may be used as functional medicine tools to support fat loss, protect muscle, and improve long-term metabolic health.

Antoine Galvani est Secrétaire Général Adjoint de la Fédération CGT Spectacle. Dans cet épisode nous évoqueront comment lui est venu son envie de se syndiquer et de s'engager de façon significative dans la protection sociale. Il donnera des exemples concrets de droits acquis par les intermittents du spectacle suite aux luttes syndicales. Nous aborderons aussi la réglementation de la pratique amateur, puis comment se professionnaliser dans la musique. Nous verrons les solutions possibles, comme le GUSO permettant l'emploi direct des artistes par les employeurs occasionnels (comme les bars, restaurants, petites collectivités, association, etc. ), ou bien les structures de production.Nous parlerons des aides à l'emploi existantes (GIP café culture, Fonpeps,...) Nous parlerons du cas particulier des artistes auteurs, pour lesquels se battent actuellement les syndicats ainsi que de l'arrivée de l'intelligence artificielle dans nos métiers. #cgtspectacle #snam-cgt #self69-cgtspectacle Pour suivre La CGT Spectacle :https://www.facebook.com/cgt.spectacle/https://www.facebook.com/snam.cgthttps://www.snam-cgt.org/https://www.facebook.com/profile.php?id=61558493123820#Pour suivre Antoine Galvani, super pianiste : http://antoinegalvani.fr Minutage :00:00:00 - Générique00:00:25 - Présentation (CGT spectacle) Actions et revendications00:20:32 - Musicien amateur, les règles00:24:53 - La professionnalisation des artistes00:25:46 - Les associations de production 9001Z00:33:20 - Le GUSO pour les employeurs occasionnels00:34:12 - Le GIP Café Culture, des aides à l'emploi pour les employeurs occasionnels00:42:12 - Le FONPEPS, les aides à l'emploi pour les structures de production00:56:45 - Les luttes sociales pour les auteurs - compositeurs01:11:00 - L'intelligence artificielle et les syndicats01:19:15 - Le conseil de la fin  Pour suivre Backline L'Interview : Sur Facebook : https://www.facebook.com/backlinelinterview/Sur Instagram : https://www.instagram.com/backline_l_interview/Site internet : http://backlinelinterview.fr Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

We talk a lot about weight. We talk a lot about health. But rarely do we talk about them together – even though they're deeply connected. The concept of weight health looks at the bigger picture: hormones, habits, and your body as a whole, rather than separate parts. Ashley Koff, a leading voice in personalized nutrition and author of the newly released book Your Best Shot, brings decades of experience helping people decode how their bodies actually work. She combines science, practical tools, and compassionate guidance to show how to tune into your hunger cues and build a personalized approach to weight health – whether you use GLP-1 medications or not. As the founder of The Better Nutrition Program, Ashley explains how traditional methods and diet culture messaging can be harmful and shares a better way to reclaim trust in your body so you can feel your best.   In this episode, you'll learn: How hormones like GLP-1, GIP, PYY, and CCK influence appetite, cravings, and weight Simple ways to optimize your weight health for lasting results The truth about GLP-1 medications and how they fit into a larger toolkit Experiments and mindset shifts to help you trust your body Tips for navigating triggering diet culture messaging Ashley's "better, not perfect" philosophy and why joy matters This conversation offers a fresh lens to understand your body, make informed choices, and filter out the noise that doesn't serve you. Resources Mentioned: The Biology of Trauma and the Path to Healing (Episode) Learn More about Ashley Koff: Book: Your Best Shot Website: The Better Nutrition Program Instagram: https://www.instagram.com/ashleykoffapproved/ Facebook: https://www.facebook.com/ashleykoffapproved   Learn More about Elise Museles:Get the Food-Mood Bundle Special Podcast Listener Offer Food Story: Rewrite the Way You Eat, Think, and Live Website: elisemuseles.com Instagram: @elisemuseles Facebook: @elisemuseles

I don't think GLP-1 meds are the answer for everyone, but I also don't think they're the villain of the story. For many people they can be genuinely life-changing, when they're used with the right support. So this episode is for anyone who's made that decision (or is seriously considering it) and wants to do it safely, sustainably, and with as much information as possible. -I can't stop you from taking these medications, but I can help you be informed: what to ask, what to monitor, what to eat, and how to protect your muscle, gut, and long-term health along the way.Today's episode is all about one of the biggest health conversations happening right now: GLP-1 medications.I'm joined by Ashley Koff, RD, to give you the straight dope on what's really going on beneath the surface: why so many of us are struggling with food noise, why some people never reach that “80% full” feeling, and what it means when your metabolic switches (the appetite and satiety systems that should be working in the background) aren't firing properly.We break down GLP-1s, starting with what happens in an optimally functioning body: the roles of hormones like GLP-1, GIP, PYY and CCK, and how they influence hunger, fullness, blood sugar, and cravings. We also talk through what side effects might be telling you, what to monitor if you do choose medication, and whether supplements have a role — including the so-called “GLP-1 boosters” you'll see everywhere.Most importantly, this episode is for anyone who wants lasting fat loss and better metabolic health, with or without drugs.Ashley Koff is a registered dietitian and founder of the Better Nutrition Program, and she trains clinicians as course director for UC Irvine's Integrative & Functional Medicine Fellowship. She's also the author of the upcoming book ‘Your Best Shot'.

Send us a textLosing weight after 40 can backfire if it's done the wrong way—and in this episode of the Strong By Design Podcast, we uncover why that matters more than ever. Coach Chris Wilson sits down with Dr. Ron Eccles to explore the growing role of peptides and GLP-based therapies in sustainable weight and fat loss. Dr. Eccles breaks down peptides in simple terms, explaining how gut hormones like GLP-1, GLP-2, and GIP influence hunger, metabolism, and body composition. Together, they discuss why weight loss alone doesn't equal better health—and how preserving muscle, protecting joints, and improving metabolic health must be part of the equation.The conversation also tackles America's declining health outcomes, the concept of the “bliss point” in eating behavior, and what truly happens after you reach your target weight. Dr. Eccles shares insights on emerging peptide technologies, common myths around GLPs, and why lifestyle factors like sleep, movement, and nutrition determine long-term success. You'll also hear real-world lessons from clinical practice, including differences between men and women and the key health metrics that actually matter. This episode is a must-listen for anyone curious about modern weight-loss solutions and how to approach them safely, intelligently, and with long-term health in mind. Time Stamps00:00 – Lose weight the wrong way: Hidden dangers for anyone over 4000:56 — Welcome to the Strong by Design podcast!02:20 – Join Coach Chris and special guest Dr. Ron Eccles03:11 – Dr. Ron's 4 pillars of life balance—and why health is a top priority05:06 – Peptides explained: What they are and how they work06:56 – Discover the peptide that started it all10:38 – GLP-1, GLP-2, and GIP: the gut peptides that silence hunger12:53 – Why losing weight isn't the same as building a better body14:48 - Discussion of the abysmal health outcomes in America16:59 – The concept of the “Bliss Point” explained19:06 – What comes next? 3 options after hitting your target21:02 – Next-level peptides: control appetite, burn fat, and save muscle26:50 – The future of peptides: No injections required29:12 – Debunking myths about GLPs33:30 – How chronic joint pain affected Dr. Eccles's wife36:33 – Weight loss differences between men and women37:56 – The 5 key metrics Dr. Eccles tracks with his clients39:18 – The science behind Alpha Shred revealed43:35 – Lifestyle factors that make peptides work47:02 – Why sleep is essential for brain health53:31 – Key advice before your peptide journey55:39 – Why some “unconventional” doctors get it right1:00:26 - Stay connected beyond the episode with Ron Eccles1:03:23 - Fun fact about the Strong by Design Podcast name1:05:23 - Please share and leave ratings & reviews for the SBD podcast! Resources:15-minute Consultation at 941-799-6583Connect with Dr Ron: InstagramStart the New Year with more Focus, Clarity & Mental Energy!Grab some Neuro-Thrive at a Discount - Use Code: SBD2026

Nutritious Life PodcastIn this timely episode of the Living a Nutritious Life Podcast, we are thrilled to welcome Ashley Koff, RD, a nationally recognized dietitian, author, and nutrition expert.About Our Guest:Ashley Koff, RD, is the founder of The Better Nutrition Program (BNP) and the author of the newly released book, Your Best Shot. An acclaimed weight-health expert and practitioner for more than 25 years, Koff is leading a transformative movement in personalized nutrition, turning “better, not perfect” choices into practical, sustainable strategies that deliver real outcomes.What You'll Learn in This Episode:- The critical role of "weight health hormones" (including GLP-1, PYY, CCK, and GIP) in metabolism, appetite, and overall well-being.- Why weight loss and health have long been separated—and how to finally bridge them for lifelong results.- How optimizing your own hormones is essential, whether or not you use GLP-1 agonist medications.- Why personalized assessment and nutrition matter more than any fad diet, supplement, or one-size-fits-all approach.Episode Highlights:- The science behind the GLP-1 hormone, how GLP-1 agonists work, and why they're reshaping weight health (and medicine!).- Ashley's signature “pizza analogy” to make customizing your nutrition plan simple and sustainable.- The most overlooked nutrients and habits that support your body's own hormonal balance and weight regulation.- A candid discussion about medication, teens, and why every individual needs a personalized approach—plus how Ashley's own story shaped this movement.About Living a Nutritious Life Podcast: Welcome to the Living a Nutritious Life podcast with Keri Glassman, MS, RDN, CDN, where we break down the latest nutrition science into smart, actionable tips to help you live your most nutritious life.On the Living a Nutritious Life podcast, Keri and her world-renowned guests cut through the noise, sharing unparalleled, forward-thinking tips, tricks, and the latest in health, wellness, and nutrition science.Based on Keri's whole-person approach to healthy living, each impactful episode extends far beyond the simplistic “get more sleep” and “eat your greens” advice. She connects the dots like no one else – like how morning yoga can make it easier to choose a healthy lunch, leading to better sleep at night.Listen as Keri and her expert guests explore the physiological and behavioral connections that explain, for example, why the common wisdom around dieting and exercising alone doesn't work, so you can finally make the meaningful changes you've been looking for.Thank you for listening in to this episode of Living a Nutritious Life. We hope you enjoyed the conversation as much as we did! If you found value in this episode, please RATE, REVIEW and SHARE.Ready to Dive Deeper? Are you ready to dive into the world of nutrition and wellness even deeper and become a certified nutrition coach? Join our amazing global community of like-minded students and alumni. Get in on the action—enroll in our Become a Nutrition Coach program at nutritiouslife.com/bnc. Keri has a lot to teach, and we're here to help you get started on your journey!Connect with Ashley on social:IG: www.instagram.com/ashleykoffapprovedWebsite: https://thebetternutritionprogram.com/Your Best Shot: https://thebetternutritionprogram.com/your-best-shot/#OrderConnect with Keri on social: Instagram: https://www.instagram.com/nutritiouslifeofficial/ Instagram: https://www.instagram.com/keriglassman/ TikTok: https://www.tiktok.com/@keriglassman Facebook: https://www.facebook.com/KeriGlassmanNutritiousLife Twitter: https://twitter.com/NutritiousLife_ LinkedIn: https://www.linkedin.com/company/nutritiouslife Pinterest: https://www.pinterest.com/nutritious_life/ Website: https://nutritiouslife.com/ Become a Nutrition Coach: https://nutritiouslife.com/bnc/Copyright © 2023-2025 Nutritious Life.#LivingaNutritiousLife #NutritiousLife Hosted on Acast. See acast.com/privacy for more information.

Happy New Year! This time of the year, most declare their resolutions - a huge majority including diet and weight loss, but what is the best way to do it?In this episode, our Chief Science Officer, Dr. Krista Kostroman, N.D., is joined by Ashley Koff, R.D., the founder of The Better Nutrition Program (BNP), the nutrition course director for UC Irvine's Susan Samueli Integrative Health Institute's Integrative and Functional Medicine Fellowship, and a faculty member at the Integrative and Functional Nutrition Academy (IFNA), where she teaches “An Integrative and Functional Nutrition Approach to Obesity and Weight Management.”She is also the author of the recently released book Your Best Shot (HarperOne, Jan. 6, 2026). With over 25 years of practice, Ashley leads a transformative movement in personalized nutrition — turning “better, not perfect” choices into practical, sustainable strategies that create meaningful health outcomes. Through patient stories and personal experience, she demonstrates that optimal health isn't just possible — it's essential to living a full life.Her work has been recognized widely: she was named one of CNN's Top 100 Health Makers, featured in InStyle as “Hollywood's Leading Dietitian,” and selected as Westin's Global Nutrition Ambassador.Join us today as we uncover the science and truth about weight health and nutrition! This includes the following highlights:What our genetics says about our weight, diet, and nutritionWhat GLP-1s arePersonalized Nutrition and how to create sustainable strategies for optimal health and weight lossHow supplements affect our diet and nutritionAshley Koff's book, “Your Best Shot”If you wish to learn more from Dr. Emily Splichal and Naboso, you may do so through the following channels:Website: https://thebetternutritionprogram.com/about/Instagram: @thebetternutritionprogramCheck out Ashley's book at: Your Best Shot: The Personalized System for Optimal Weight Heath - GLP-1 Shot or Not (Harper One, January 6, 2026). Out now wherever books are soldThe real revolution of the GLP-1 shots is the insight that the body regulates appetite and more with the hormones GLP-1, GIP, PYY, and CCK—and with Your Best Shot in hand, you can learn to optimize their function and your weight health for life______________________________________________________Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram: @dnatalkspodcastThe DNA Company Instagram: @thednacoThe DNA Company's Official Tiktok Account: @thednaco3______________________________________________________Medical Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle a wide-ranging mailbag episode with listener questions from the U.S., UK, and Europe. Topics include unexpected weight regain on GLP-1s, post-meal sleepiness and hypoglycemia, metabolic dysfunction despite normal labs, GLP-1 dosing strategies, and why these medications are about metabolism, not appetite suppression.Key Questions AnsweredWhy can weight regain happen on GLP-1s even when habits haven't changed?How do leptin, ghrelin, injury, stress, and under-fueling affect weight regulation?What does it mean if you get extremely sleepy after meals—is it hypoglycemia?Do GLP-1s increase insulin in a harmful way for non-diabetics?Can you have metabolic dysfunction with normal A1C, cholesterol, and blood pressure?Do GLP-1 medications “wear off,” and how should dosing be adjusted long term?Are GLP-1s just appetite suppressants—or true metabolic treatment?Is it possible to undo decades of calorie counting and restriction-based thinking?What are the risks of the return to extreme thinness in celebrity culture?Key TakeawaysCalories don't explain metabolism. GLP-1 and GIP work across the brain and body—repairing signaling, not just reducing appetite.Leptin matters after dieting. Years of restriction and weight cycling can weaken leptin signaling, making the brain defend weight gain.Fueling is foundational. Medication can't replace adequate food, sleep, and recovery.Post-meal fatigue is a clue. Reactive hypoglycemia is common and often misunderstood.Lowest effective dose wins. GLP-1 success is about pacing, not racing to the max dose.Chasing the “last 10 pounds” can backfire. Cosmetic restriction can create new metabolic problems.Dr. Cooper's Actionable TipsIf weight gain appears after injury or stress, focus first on sleep, regular meals, and full fueling, not restriction.Suspected hypoglycemia? Ask about a mixed meal tolerance test to assess glucose and insulin response.Stay on the lowest GLP-1 dose that's working and adjust only when progress truly stalls.Push back on “appetite suppressant” language—these meds amplify hormones your body already makes.Notable Quote“GLP-1s aren't about eating less—they're about strengthening metabolic signaling” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/Podcast Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.comFat Science breaks diet myths and advances the science of real metabolic health. No diets, no agendas—just science that makes you feel better. This show is informational only and does not constitute medical advice.

This week, I gave the wrapup for popular health news and topics in 2025. People were interested in longevity and healthy aging; those notorious GLP-1 and GIP drugs for weight loss; the best vitamins, minerals, and supplements for health. Big stories dealt with when the body starts aging rapidly; protein powders and lead levels; measles outbreaks […]

Ryan Sternagel—co-founder of The Stern Method, Going Integrative Plus (GIP+), and Our Health Naturally—joins Dr. Karlfeldt to share the real story behind his family's mission: in 2014, Ryan and his wife Teddy learned their son Ryder had stage four neuroblastoma just eleven days before his first birthday. What followed was a crash course in advocacy, research, and resilience—plus a decades-worth of integrative insights earned the hard way. If you've ever felt overwhelmed by a diagnosis, pressured into one path, or unsure how to “do everything” without losing your mind, this conversation is for you.In this episode, Ryan walks through the moment they knew something was wrong, the medical runaround that nearly delayed answers, and how they learned to push for imaging, ask better questions, and make decisions strategically—especially when facing institutional pressure. They discuss the chess match many families experience in pediatric oncology, including navigating treatment expectations, scan decisions, and the importance of building a supportive plan that addresses nutrition, environment, and mindset alongside medical care. Ryan also shares the evolution from documenting their journey online to creating a searchable library of expert integrative oncology guidance through GIP+—so families can learn directly from top holistic cancer doctors and “test-drive” approaches that resonate.You'll also hear Ryan's perspective on “cake vs. frosting”: why foundational daily practices (circadian rhythm, nature time, reducing toxic load, nervous system regulation, and belief/mindset work) often matter more than any shiny new therapy—yet how select advanced tools may fit into a larger integrative strategy. This is a grounded, motivating listen for patients, caregivers, and practitioners who want a more empowered, organized way forward.Key Topics CoveredRyder's stage 4 neuroblastoma diagnosis and the early warning signs that were missedSelf-advocacy in pediatrics: pushing for ultrasound/MRI and trusting intuitionNavigating hospital systems, treatment escalation, and the realities of compliance pressureBuilding an “integrative support stack”: nutrition, juicing, supplements, IV vitamin C, and lifestyleThe importance of organization and implementation: turning information into a workable scheduleNon-toxic living and environmental control (EMFs, chemicals, lighting, plastics, circadian rhythm)Mindset as medicine: trauma work, belief systems, meditation/breathwork, and daily centering practices“Cake vs. frosting”: foundational habits vs. advanced/experimental therapiesRyan's “talent scout” approach: finding top integrative cancer doctors and filtering conflicting infoGIP+ as a model for weekly expert access, Q&A, and a searchable archive of integrative guidanceTo learn more about Ryan and Teddy's work, explore The Stern Method, their step-by-step framework for implementing integrative cancer support in real life, at https://thesternmethod.com/ Listeners can also check out OUR 7, their comprehensive epigenetic nutrient blend from Our Health Naturally, available at https://ourhealthnaturally.com/ use the discount code KARLFELDT20 to receive 20% off from December 16–31, 2025, and KARLFELDT for 10% off ongoing orders after that.For those seeking direct access to top integrative cancer doctors, weekly guidance, and a searchable archive of expert insights, join Going Integrative Plus (GIP+) at https://goingintegrativeplus.com/and use the code KARLFELDT50 for 50% off your first month subscription. -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

A common referral scenario involves hospital clinicians referring a dying patient to hospice. This circumstance gives rise to questions relating to hospice eligibility, the appropriate level of hospice care, and the expectation of the patient and the hospital. In this episode, Husch Blackwell's Meg Pekarske and Bryan Nowicki address these questions and provide insights into effectively managing this situation.Additional resources:Medicare Benefit Policy Manual Chapter 9 Excerpt - General Inpatient Care

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

https://www.otplinks.com 0:00 Welcome & today's focus: Retatrutide and “chasing the biggest number” 1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping 2:10 How Dave first heard about retatrutide (work trip, early phase 1 data) 3:35 Flashback clip: early excitement about retatrutide phase 3 trials 4:40 Why this new retatrutide data feels different for obesity medicine 5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population 7:00 Headline results: 28.7% average weight loss, surgery-level efficacy 8:47 Breaking down weight loss by dose (9 mg vs 12 mg; 25–35% loss rates) 11:05 What “efficacy estimate” really means (race-track analogy) 13:28 Real-world view: treatment-regimen estimate (20–23.7%) vs trial ideal 15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ 18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences) 21:02 Why the lower doses matter & who actually needs 30% weight loss 24:15 From “just make the scale go down” to quality of weight loss & body composition 28:05 Future focus: health, longevity, and peptides beyond hitting goal weight 30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & “talk to your doctor” 34:38 How retatrutide changes the next decade of obesity treatment conversations 37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook 40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review 45:20 Why small-molecule oral GLP-1s aren't the same as injectable peptides 48:40 New topic: Indiana “Safe Drug Act of 2025” and why Dave is concerned 51:02 Production caps, “essentially a copy” language & shifting power from prescribers to FDA 54:28 How the bill undermines personalization while ignoring real safety tools 57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting 59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors 1:02:05 Call to action: petition at otplinks.com & why patient voices matter 1:05:10 Change.org impact, media attention & centering the patient perspective 1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a myriad of transformative advancements and strategic shifts within these industries, illustrating the profound impact of innovation and regulatory changes on healthcare.Eli Lilly's recent strides in obesity treatment highlight a significant scientific breakthrough with their novel drug, retatrutide. Currently in phase 3 trials, this triple agonist targets GLP-1, GIP, and glucagon receptors, achieving an extraordinary 28.7% weight loss in participants. Additionally, it demonstrated a 75.8% reduction in knee osteoarthritis pain. Yet, the journey to this milestone wasn't without challenges. The trials saw a higher discontinuation rate than earlier studies, reminding us of the delicate balance between efficacy and patient tolerability—a consistent theme in obesity pharmacotherapy as developers strive to maximize benefits while minimizing adverse effects.In a testament to the global nature of drug development, Zealand Pharma has embarked on a $2.5 billion collaboration with a burgeoning Chinese biotech firm. This partnership aims to advance oral cardiometabolic therapies, underscoring the crucial role of strategic alliances in accessing innovative scientific platforms and expanding market reach.Rezolute faced a significant setback with a disappointing phase 3 trial for its hypoglycemia treatment, resulting in an 87% drop in stock value. This starkly illustrates biotech's inherent volatility and the critical importance of robust clinical trial design to mitigate financial risks associated with unsuccessful outcomes.Meanwhile, Moderna is leveraging Nanexa's expertise in long-acting formulations to enhance injectable therapy delivery systems. This collaboration is indicative of a broader industry trend focused on optimizing drug delivery technologies to boost efficacy and patient compliance.Operational restructuring is also evident as Pfizer implements cost-cutting measures, including layoffs in Switzerland, as part of broader strategic initiatives to optimize operations amid rising R&D costs and pricing pressures. Simultaneously, Chris Boulton's transition from Amgen to Prolynx underscores the fluid movement of talent within the industry—a reflection of ongoing strategic realignments.Regulatory landscapes are shifting as well. The FDA's approval of the first non-drug at-home treatment for depression marks an expansion into alternative therapeutic modalities beyond traditional pharmaceuticals. This wearable device offers adults with major depressive disorder a novel treatment option, integrating technology into mental health care—a promising addition to holistic treatment strategies.In another significant regulatory update, Teva Pharmaceuticals agreed to delist numerous patents from the FDA's Orange Book following an FTC ruling. This move is anticipated to foster increased generic competition and potentially lower medication costs for conditions like asthma and diabetes—a critical shift towards greater market accessibility.The FDA has also finalized guidance on promotional materials for biologics and biosimilars, standardizing advertising practices to ensure accurate representation of these products' efficacy and safety profiles amidst an expanding biologics market.Moreover, the FDA has launched its Commissioner's National Priority Voucher Pilot Review Program to expedite critical drug approvals. The first beneficiary under this program was USAntibiotics with Augmentin XR, signaling a potential shift towards more rapid access to essential medications.On the international policy front, recent developments between the UK and US have led to reductions in medicine rebate rates within the UK. This adjustment could lead to increased spending on new medicines, indicating more favorable conditions for pharmaceutical Support the show

Book a FREE functional health discovery call HERE. If you've been hearing the buzz about Ozempic, Wegovy, Mounjaro, or other GLP-1/GIP medications, you're not alone. But there's so much more to this conversation than weight loss. In this episode, Tanya breaks down the real science behind GLP-1 receptor agonists — what they are, how long they've been around, and the growing research that shows benefits far beyond the scale. From heart and kidney protection to inflammation reduction and body composition support, Tanya explains what midlife women need to know before jumping on the bandwagon. She also shares her personal journey exploring micro-dosing peptides (including tirzepatide and NAD+) — what she's learning, what's working, and how she's helping women make informed, safe, and personalized decisions through trusted telemedicine partnerships. Whether you're considering GLP-1s, curious about peptides, or simply trying to build energy and longevity in midlife, this episode will help you understand the research, the real benefits, and the importance of building your health on solid foundations. You'll Learn: What GLP-1 receptor agonists are and how they work in the body The long-term research behind GLP-1s — including heart, kidney, and liver health benefits What “micro-dosing” really means (and what we don't yet know) How peptides like tirzepatide and NAD+ may support energy, inflammation, and recovery Why foundational health habits — nutrition, muscle, rest, stress regulation — matter more than any injection or supplement Practical, real-world takeaways for midlife women seeking sustainable health and vitality Disclaimer: This episode is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare provider before beginning or changing any health protocol or medication.   I hope this episode blesses you! Xoxo, Tanya Episode Resources: Episode Catalog   My trusted Supplement Dispensary: Aligned Vitality Fullscript Dispensary My trusted Telehealth Peptide Provider:  EllieMD_Tanya Engesether *I do get a small commission when you use one of the above affiliate links. 3 Ways To Connect With Me: 1️⃣COACHING: Are you READY to Lead Well, Live Well and BE Well? Book a FREE discovery call with me to find out more about functional health coaching. It's the accountability and guidance you need to reclaim your health and happiness! ➡︎ https://alignedvitalityhealth.com/coaching   2️⃣ FACEBOOK: Become part of our Supportive Facebook Group. Connect, share, and learn with others navigating life and leadership ➡︎ https://alignedvitalityhealth.com/community   3️⃣ CONTACT: Leave me a question or comment ➡︎ https://alignedvitalityhealth.com/contact   "Yes! Finally, a podcast helping others become the thriving leaders they're meant to be outside of hustle-culture! This is an amazing resource! Thank you so much for sharing and helping us become Spirit-driven, peaceful leaders!"    If you can relate, please consider rating and reviewing my show! It helps me reach more people – just like you – to help them change their future. Don't forget to follow the show so you don't miss any episodes! And, if you're feeling really generous, I'd be SO honored if you would share this podcast with someone.   Click here to view our privacy policy.   Reminder:  The information you hear on this show is not meant to diagnose, treat, cure or prevent disease.  It is for educational purposes only. Always consult with your own health practitioner before you make any changes to your health.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

CME credits: 0.25 Valid until: 03-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/early-action-in-obesity-transforming-practice-improving-outcomes/36273/ Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights real-world evidence and addresses the shift from weight-centric to holistic clinical approaches, as seen in updated European and Canadian guidelines. Monitoring strategies—including satiety, nutritional status, physical activity, and side effects—are explored as key elements in long-term obesity care. The dialogue underscores the chronic nature of obesity and the importance of patient-centered care. =

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's episode is a powerful, honest conversation with three incredible women who are taking their health into their own hands. Joined again by the brilliant Kimberly Cunningham, NP, we're talking about what it really looks like to reclaim your body, your confidence, and your joy after 40.Elizabeth, Andrea, and Orion share their deeply personal journeys with hormone replacement therapy and GLP-1/GIP weight-loss medications, what led them to seek help, what changed, what surprised them, and how their lives have transformed physically, mentally, and emotionally.This roundtable is honest, tender, eye-opening, and full of information that women are rarely given. If you've ever struggled with weight, mood swings, fatigue, food noise, or that feeling of “I don't recognize myself anymore,” this episode will feel like a breath of fresh air.Kimberly also breaks down the science behind GLP-1/GIP medications, HRT, PCOS, perimenopause, metabolic health, insurance barriers, and the stigma so many women carry, when the truth is, this is biology, not moral failure.This is the conversation I wish I had decades ago. And I hope it helps you feel seen, validated, and supported on your own path.Go to michellefox.com/podcast for full show notes. Hosted on Acast. See acast.com/privacy for more information.

In this bonus episode of A Friend for the Long Haul, I get to talk with Dr. Julia Moore Vogel from Scripps Research. I slid into her DMs to see if she'd like to join me to discuss the recruitment and structure of a new clinical trial examining the effects of tirzepatide, a dual GLP-1 and GIP agonist, on long COVID symptoms. Dr. Vogel is the Senior Program Director, The Participant Center, All of Us Research Program. She's a fellow long hauler and "manages The Participant Center (TPC) for the All of Us Research Program which is charged with recruiting and retaining 350,000 individuals that represent the diversity of the United States. TPC aims to make it possible for interested individuals anywhere in the US to become active participants, for example by collaborating with numerous outreach partners to raise awareness, collecting biosamples nationwide, returning participants' results and developing self-guided workflows that enable participants to join whenever is convenient for them." (Thanks for letting me borrow the blurb, Scripps.

Doctor Mau Informa ®️#drmauinforma Mounjaro (Tirzepatida): ¿Magia o Ciencia?

Precise receptor mapping is reshaping how we understand incretin biology. David Hodson explains how GPCR-targeted chemical probes reveal where GLP-1 and GIP receptors actually signal across pancreas and brain—and what this means for metabolic drug design.Learn how these tools refine gpcr drug discovery, clarify receptor internalization, and guide next-gen therapeutics.

Send us a textChris Broomhead is a bodybuilder, personal trainer and coach, educator, entrepreneur, and advocate for science-backed performance & health. After 14+ years competing in bodybuilding, he is now dedicated to cutting through hype in health and performance.Today, Chris focuses on GLP-1s and peptides, such as Semaglutide, Tirzepatide, Retatrutide, teaching how science and lifestyle work together for resilience, longevity, and transformation.Find Chris at-IG- @Chris_Broomhead_researchYT- @Chris Broomhead CoachingFind Boundless Body at- myboundlessbody.com Book a session with us here!

Solar Dominates 2025 Energy Additions; Nuclear Sees Major Expansion Welcome to our weekly Renewable Energy Briefing! Stay informed on the latest industry trends.  Episode #38 Briefing Highlights: -U.S. government and Westinghouse in $80 billion deal for new nuclear power  -Global Infrastructure Partners (GIP) in a massive deal to acquire utility giant AES  -New federal report shows solar made up almost three-quarters of all new power in 2025 (19GW) -Federal government cancels $7 billion for low-income solar; over 20 states are now suing Solar continues its dominance in 2025, accounting for 19 GW of the 26 GW of new U.S. energy capacity added this year. Meanwhile, the nuclear renaissance accelerates as the U.S. government and Westinghouse announce an $80B deal that reshapes the future of baseload power. Benoy and David break down the biggest transactions—including GIP's acquisition of AES—and the implications of federal policy changes, such as the Trump administration canceling $7B in solar grants aimed at low-income communities. Get the clean energy insights you need in five minutes. Join us for a comprehensive analysis that combines expert commentary with up-to-the-minute news, offering you a strategic overview of the renewable energy market. Don't miss out on the crucial details that can impact your investment decisions. Tune in weekly for your essential dose of Renewable Energy insights! Host Bio: Benoy Thanjan Benoy Thanjan is the Founder and CEO of Reneu Energy, solar developer and consulting firm, and a strategic advisor to multiple cleantech startups. Over his career, Benoy has developed over 100 MWs of solar projects across the U.S., helped launch the first residential solar tax equity funds at Tesla, and brokered $45 million in Renewable Energy Credits (“REC”) transactions.   Prior to founding Reneu Energy, Benoy was the Environmental Commodities Trader in Tesla's Project Finance Group, where he managed one of the largest environmental  commodities portfolios. He originated REC trades and co-developed a monetization and hedging strategy with senior leadership to enter the East Coast market.   As Vice President at Vanguard Energy Partners, Benoy crafted project finance solutions for commercial-scale solar portfolios. His role at Ridgewood Renewable Power, a private equity fund with 125 MWs of U.S. renewable assets, involved evaluating investment opportunities and maximizing returns. He also played a key role in the sale of the firm's renewable portfolio.   Earlier in his career, Benoy worked in Energy Structured Finance at Deloitte & Touche and Financial Advisory Services at Ernst & Young, following an internship on the trading floor at D.E. Shaw & Co., a multi billion dollar hedge fund.   Benoy holds an MBA in Finance from Rutgers University and a BS in Finance and Economics from NYU Stern, where he was an Alumni Scholar. Connect with Benoy on LinkedIn: https://www.linkedin.com/in/benoythanjan/ Learn more: https://reneuenergy.com https://www.solarmaverickpodcast.com     Host Bio: David Magid David Magid is a seasoned renewable energy executive with deep expertise in solar development, financing, and operations. He has worked across the clean energy value chain, leading teams that deliver distributed generation and community solar projects. David is widely recognized for his strategic insights on interconnection, market economics, and policy trends shaping the U.S. solar industry. Connect with David on LinkedIn: https://www.linkedin.com/in/davidmagid/   If you have any questions or comments, you can email us at info@reneuenergy.com.  

Today, we're tackling a question that comes up often in peptide, weight loss, and nutrition clinics: why does one person see great results with semaglutide, while another responds better to tirzepatide—or even retatrutide? If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ All three peptides target the incretin system, but they act in slightly different ways—and those differences can dramatically affect outcomes. Let's start with the basics. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the gut hormone GLP-1, which increases insulin when blood sugar is high (to help lower blood sugar), suppresses glucagon (which also decreases blood sugar), and slows gastric emptying. It also enhances satiety—so you feel full longer and eat less. Tirzepatide is a dual agonist, acting on both GLP-1 and GIP receptors. GIP—glucose-dependent insulinotropic polypeptide—also helps with insulin secretion to lower blood sugar, increases fat metabolism, and may reduce some of the GI side effects seen with GLP-1 alone. Retatrutide, the newest in the lineup, is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Retatrutide lightly activates the glucagon receptor while strongly activating GLP-1 and GIP receptors, which help regulate blood sugar and boost insulin secretion. This keeps blood sugar stable—or even improves it. Beyond blood sugar, glucagon also ramps up metabolism and calorie burning. By gently engaging glucagon receptors, retatrutide can increase energy expenditure and support fat loss without triggering large blood sugar spikes. So how do you decide which one might work best? Let's walk through common clinical situations. Patients with Hypothyroidism Let's talk about hypothyroidism. People with hypothyroidism often have slower metabolism, making weight loss more difficult even with a balanced diet. Low thyroid hormone levels slow calorie burning and energy use, so weight gain can occur more easily. For these patients, semaglutide is a reliable starting point—it helps regulate appetite and caloric intake. If progress plateaus, tirzepatide or retatrutide may provide an edge by boosting energy expenditure and fat oxidation, essentially "jump-starting" a slower metabolism. Patients with PCOS (Polycystic Ovary Syndrome) What about patients with PCOS (polycystic ovary syndrome)? Insulin resistance is common in PCOS, often leading to higher androgen levels (e.g., testosterone) and symptoms like irregular periods, acne, and excess hair growth. Hormonal changes also affect appetite-regulating hormones, increasing hunger and cravings. Both GLP-1 and dual agonists have proven effective in managing metabolic and reproductive aspects of PCOS. Typically, we start with semaglutide to improve weight, insulin sensitivity, androgen levels, and menstrual regularity. After a few months, if weight loss plateaus or cravings remain high, we may switch to tirzepatide. The added GIP activity enhances fat metabolism, insulin control, and may further support hormone regulation and ovulation. The key is starting with what's well-studied and tolerated, then stepping up if additional metabolic or reproductive support is needed. Type 2 Diabetes (T2DM) The next medical condition I'd like to talk about is type 2 diabetes (T2DM). Weight gain in T2DM often stems from insulin resistance. Cells don't respond effectively to insulin, prompting the pancreas to relelase more. High insulin levels encourage fat storage, particularly around the abdomen, while elevated blood sugar can increase hunger and cravings. Some diabetes medications, like insulin or sulfonylureas (e.g., glipizide or glyburide), can also contribute to weight gain. All three drugs lower blood sugar and promote weight loss, but tirzepatide currently shows the strongest combined A1c reduction (average blood sugar over the past 2 to 3 months) and weight loss. GIP and GLP-1 work together to enhance insulin response more effectively than GLP-1 alone. Retatrutide is in phase 3 trials, with potential FDA approval as early as 2027. Its glucagon receptor activity may offer additional glucose regulation and energy expenditure benefits. Patients with >15% Weight Loss Goals Okay, let's talk about weight loss goals and how this ties into the decision process for choosing a weight loss medication. For those patients looking to lose more than 15% of their total body weight, tirzepatide or retatrutide are likely to deliver greater results. Clinical data show semaglutide can achieve up to 15% total weight loss while tirzepatide can achieve up to 22% and retatrutide up to 24%. That said, semaglutide remains a highly effective option for weight loss. However, if progress begins to plateau, transitioning to a dual or triple agonist may help restart weight loss and push past that plateau. Pre- and Postmenopausal Women What about peri- and postmenopausal patients? Hormonal shifts during perimenopause and menopause slow metabolism and can increase cravings. Declining estrogen promotes abdominal fat storage and affects appetite-regulating hormones. Semaglutide helps with appetite control and gradual fat loss, while tirzepatide's GIP activation can further support fat metabolism when estrogen levels drop. Patients with Heart Disease or High Cholesterol The last group of patients I'd like to discuss is patients with heart disease (e.g., heart failure, stroke, heart attack, or even atherosclerosis) or people with high cholesterol. Semaglutide has the strongest cardiovascular outcomes data, reducing major adverse cardiac events by 20% and improving LDL cholesterol (bad cholesterol) and blood pressure. Tirzepatide shows promise for heart and lipid benefits, but those trials are still ongoing. For patients with prior heart attack, stroke, or severe coronary artery disease, semaglutide remains the safest evidence-backed starting point—unless intolerable side effects or weight loss resistance occur. Tolerability Now I want to switch gears a bit and talk about side effects and tolerablity of these peptides. Some patients experience stomach-related side effects like nausea, bloating, or acid reflux on semaglutide. Generally, tirzepatide tends to cause fewer GI side effects, likely due to GIP balancing GLP-1 activity in the gut. So patients struggling with nausea or other stomach-related side effects may find tirzepatide more tolerable. Just something to keep in mind. Individualizing Therapy Lastly, I want to highlight the importance of individualizing weight loss peptide treatments. There's no one-size-fits-all approach when it comes to these therapies. Clinicians should carefully consider a patient's goals, medical history, current medications, and tolerance before choosing the most appropriate option. Setting realistic expectations from the start is essential. It's important to remember that everyone's body responds differently because of factors like hormones, genetics, metabolism, gut microbiome balance, and lifestyle habits. These differences influence how effectively a peptide therapy works and how well it's tolerated. That's why ongoing monitoring and follow-up are such an important part of the process. Providers track progress, adjust dosing when needed, and switch medications if weight loss plateaus or side effects occur. The goal isn't just to lose weight quickly—it's to create a safe, sustainable plan that supports long-term metabolic health and helps patients feel their best. Thanks for listening to The Peptide Podcast.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Until next time, be well, and have a happy, healthy week.

Hitting a metabolic wall in midlife? You're not alone — and you're not broken. In this episode, Michele Folan, midlife health coach and former diabetes industry insider, breaks down the science (and the truth) behind microdosed GLP-1 and peptide therapy for women 40+.Drawing on many years in diabetes and cardiovascular health, Michele explains how incretin hormones like GLP-1 and GIP regulate appetite, satiety, and insulin sensitivity — and why they've become game-changers for both metabolic and weight health. You'll hear:The wild origin story of GLP-1 (hint: it starts with the Gila monster)Why early GLP-1 drugs revolutionized diabetes careHow microdosing protocols now support fat loss while protecting lean muscleThe real goals: improved A1C, fasting insulin, lipids, inflammation, and energyThis isn't about shortcuts — it's about layering science-backed tools onto strong habits: ✅ Lifting heavy ✅ Eating enough protein ✅ Prioritizing recovery ✅ Partnering with trusted, physician-led telehealth and vetted compounding pharmaciesMichele also dives into other longevity peptides that support sleep, recovery, cognition, skin, and hair health — plus the role of NAD+ in cellular repair and energy.If you've been “doing everything right” and still feel stuck, this episode connects the dots between modern peptide therapy and midlife metabolism — with zero hype and total transparency.

Can medications like Ozempic and Mounjaro actually do more than help you lose weight? This minisode features highlights from our full conversation, which premiered October 7th, 2025. Watch the full episode here → https://youtu.be/AcVIiy201H4?si=nlaFL3JnoZHxQVFh Dr. Rocio Salas-Whalen and I explore the difference between GLP-1, GIP, and triple-agonist drugs — and what's next in obesity medicine, how estrogen changes after 40 drive midsection weight gain and inflammation, why GLP-1s reduce cancer and Alzheimer's risk through anti-inflammatory and neuroprotective effects and how obesity and insulin resistance impact fertility and PCOS — and how GLP-1s can help.If you've ever wondered whether GLP-1s are just “weight loss shots” or a real step forward in metabolic and brain health — this “minisode” is a must-listen. *** Follow Dr. Salas-Whalen: Instagram: @drsalaswhalen TikTok: @drsalaswhalen @strengthmd @thedryrevolution *** I'm Louisa Nicola — clinical neuroscientist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Topics discussed: 00:00 – Intro 00:04  – The Probiotic GLP-1 Myth 00:19 – The “iPhone Evolution” of GLP-1 Drugs 00:52 – GLP-1 vs GIP vs Triple Agonists Explained 01:24 – Phase 3 Results & Massive Weight Loss Outcomes 01:38 – The Role of Glucagon in Weight Loss 01:56 – Menopause, Estrogen & Midlife Weight Gain0 3:06 – The “Fat Shift” After 40 04:01 – Can You Combine HRT and GLP-1s? 06:17 – “Willpower” vs Biology in Obesity 07:49 – The Genetic and Hereditary Roots of Obesity 08:57 – Breaking the Transgenerational Cycle 09:30 – Thyroid Cancer Myths and GLP-1 Safety 10:49 – GLP-1s and Breast Cancer Prevention 12:06 – Inflammation as the Root of Disease 12:28 – Neuroprotection and Alzheimer's Prevention 13:17 – GLP-1s, PCOS & Fertility Benefits 13:53 – The Positive Ripple Effect on Mental Health 14:21 – GLP-1s Reduce Alzheimer's Risk by 33% 14:58 – The Future of Metabolic Health Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you doing all the right things — eating well, balancing your hormones, supporting your gut, getting your steps in — but the scale still isn't budging?You're not crazy. You're not lazy. And you're definitely not alone.In this episode of The Period Whisperer Podcast, I'm diving into one of the most talked-about — and misunderstood — tools in midlife health: peptide therapy. Specifically, we're talking about GLP-1s and GLP-1/GIP + B12 blends, and how microdosing these peptides can help support your metabolism, energy, and weight loss without extreme diets or overexercising.I'll walk you through: ✨ What GLP-1 and GIP peptides actually are — and how they work with your body (not against it) ✨ The difference between traditional GLP-1s and the microdose GLP-1/GIP + B12 stack ✨ Why it's not cheating to get help supporting your metabolism in perimenopause ✨ The real reasons women get “stuck” with their weight in midlife — and how peptides can help rebalance blood sugar, reduce inflammation, and calm “food noise” ✨ Why microdosing is my preferred approach (plus the incredible results I've seen in my clients and my wife!) ✨ The foundational lab markers to check before starting any peptide protocolIf you've been feeling stuck — even though you're doing everything right — this episode will help you see why it's not your fault, and how science-backed peptide therapy might be the missing piece to help your body respond again.

SUPPORT OUR WORK: OTPLinks.com

In this episode of The Health Revival Show, Liz & Becca break down Retatrutide—a new GLP-1, GIP, and glucagon receptor agonist that's making waves in the functional health and metabolic space. Is it really “Ozempic on steroids”? They cut through the hype and bring the context no one's talking about—the importance of muscle preservation, insulin sensitivity, thyroid health, and how to use these tools responsibly (or if at all). Whether you're considering peptides or just curious about this next-gen weight loss compound, this episode delivers the no-BS truth.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover the shocking assassination of Charlie Kirk, Russian drones breaching NATO airspace, Trump's war on Venezuela's cartels, Mexico's tariff fight with China, a pharmaceutical victory in Tennessee, and new revelations in the 9/11 families' lawsuit against Saudi Arabia. From political violence at home to dangerous escalations abroad, today's brief carries heavy news on a day of prayer and remembrance.   Charlie Kirk Assassinated in Utah: The 31-year-old Turning Point USA founder was gunned down while speaking at Utah Valley University. President Trump called him “a martyr for truth and freedom” and ordered flags at half-staff. Video shows a sniper shot to the neck from a rooftop as Kirk addressed thousands of students. MSNBC sparked outrage with coverage that suggested Kirk's “awful words” made his death inevitable. Bryan warns, “The seal has now been broken: if you make those arguments or say those words, you're fair game too.”   Russian Drones Violate Polish Airspace: NATO confirms 19 Russian drones flew over 150 miles into Poland, with several shot down by Dutch and Polish jets. Bryan cautions that even an accident could spark a “Gulf of Tonkin–like incident” dragging NATO into direct war with Moscow.   Trump Escalates War on Venezuela's Cartels: After U.S. forces sank a drug boat killing 11, critics accuse Trump of overstepping presidential authority. War Secretary Pete Hegseth countered: “This strike sent a clear message: If you traffic drugs toward our shores, the United States military will stop you cold.”   Mexico Tariffs Chinese Imports: President Claudia Sheinbaum hikes tariffs on Chinese cars and textiles to 50 percent, aiming to shield Mexican workers and appease Trump's demands to close tariff loopholes. Bryan notes this could undercut Beijing's backdoor into U.S. markets.   Saving U.S. Antibiotics in Tennessee: Trump brokers a deal forcing Walmart and McKesson to buy amoxicillin from Bristol, Tennessee, rescuing America's last antibiotic factory from collapse. “Don't bet against America,” Bryan says, “because with leadership that actually loves this country, we will win.”   9/11 Families' Lawsuit Against Saudi Arabia Advances: A New York judge allows families to pursue claims that Saudi intel officers Omar al-Bayoumi and Fahad al-Thumairy aided hijackers. ProPublica reports al-Bayoumi was a Saudi intel asset in the U.S. coordinating with the GIP. Bryan calls for Trump to declassify CIA files: “It's time for some sunlight on what did or didn't happen that horrific day.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Take your personal data back with Incogni! Get 60% off an annual plan at incogni.com/TWR and use code TWR at checkout.     Keywords: Charlie Kirk assassination Utah, Trump martyr for truth, MSNBC Charlie Kirk coverage, Russian drones Poland NATO, Trump Venezuela drug cartels strike, Pete Hegseth drug cartels al Qaeda, Mexico tariffs Chinese imports Sheinbaum, Trump tariff war China backdoor, U.S. antibiotics Bristol Tennessee amoxicillin, Walmart McKesson Trump drug deal, 9/11 families lawsuit Saudi Arabia, Omar al-Bayoumi Saudi intel, Fahad al-Thumairy Saudi cleric, CIA Saudi 9/11 declassification